Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 12482. Отображено 100.
13-12-2012 дата публикации

Isoxazoline derivatives as insecticides

Номер: US20120316124A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

The present invention relates to compounds formula (I), wherein P is P1, P2, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A 1 , A 2 , A 3 , A 4 , G 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 17 , R 18 , R 19 and R 20 are as defined in claim 1 ; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising the compounds of formula (I) and to methods of using the compounds of formula (I) to control insect, acarine, nematode and mollusc pests.

Подробнее
27-12-2012 дата публикации

Triarylamine Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device

Номер: US20120330025A1
Принадлежит: Semiconductor Energy Laboratory Co Ltd

A novel triarylamine compound having a bipolar property is provided. The triarylamine compound can be used for a hole-injection layer, a hole-transport layer, a light-emitting layer, or an electron-transport layer in a light-emitting element. The triarylamine compound can also be used as a host material with a light-emitting material which emits relatively short-wavelength light, in a structure where the host material and the guest material constitute a light-emitting layer. The triarylamine compound of the present invention is a fluorescent compound and therefore can also be used as a light-emitting substance of a light-emitting layer. A light-emitting element having high emission efficiency is provided. A light-emitting device, an electronic device, or a lighting device having low power consumption is provided.

Подробнее
28-03-2013 дата публикации

Reversed biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators

Номер: US20130079271A1
Принадлежит: Individual

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

Подробнее
28-03-2013 дата публикации

RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF

Номер: US20130079360A1
Принадлежит:

The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium. 1. (canceled)2. A crystalline form of Raltegravir potassium selected from:{'figref': [{'@idref': 'DRAWINGS', 'FIG. 2'}, {'@idref': 'DRAWINGS', 'FIG. 31'}], 'sup': 13', '13', '13, 'a) crystalline Form V of Raltegravir potassium, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.0, 11.9, 18.2 and 26.6 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in ; a solid-state C NMR spectrum with signals at 121.9, 144.0, 149.3 and 170.3±0.2 ppm; a solid-state C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 111.9, 134.0, 139.3 and 160.3±0.1 ppm; a solid-state C NMR spectrum substantially as depicted in ; and combinations thereof; and'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, 'b) crystalline Form IV of Raltegravir potassium, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.5, 7.5, 8.1, 18.4 and 23.2 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in ; and combinations thereof.'}3. The crystalline Raltegravir potassium Form V according to claim 2 , characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.0 claim 2 , 11.9 claim 2 , 18.2 and 26.6 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in ; a solid-state C NMR spectrum with signals at 121.9 claim 2 , 144.0 claim 2 , 149.3 and 170.3±0.2 ppm; a solid-state C NMR spectrum having ...

Подробнее
28-03-2013 дата публикации

TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

Номер: US20130079374A1
Принадлежит: Takeda Pharmaceutical Company Limited

The present invention provides a compound represented by the formula 123-. (canceled)26. The compound of claim 24 , wherein Ris Calkyl optionally having substituent(s) claim 24 , Ccycloalkyl optionally having substituent(s) or Calkenyl optionally having substituent(s).27. The compound of claim 24 , wherein Ris a hydrogen atom or Calkyl optionally having substituent(s).28. The compound of claim 24 , wherein Ris a hydrogen atom or Calkyl optionally having substituent(s).29. The compound of claim 24 , wherein Ris a hydrogen atom claim 24 , a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s).30. The compound of claim 24 , wherein Ris a hydrogen atom claim 24 , Calkyl optionally having substituent(s) claim 24 , Calkenyl optionally having substituent(s) or amino optionally having substituent(s).31. The compound of claim 24 , wherein Rand Rare the same or different and each is a hydrogen atom claim 24 , a halogen atom claim 24 , hydroxy optionally having a substituent or Calkyl optionally having substituent(s).32. The compound of claim 24 , wherein Ris Calkyl optionally having substituent(s) claim 24 , Ccycloalkyl optionally having substituent(s) or Calkenyl optionally having substituent(s);{'sup': '2', 'Ris a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s);'}{'sup': '3', 'sub': 1-6', '2-6, 'Ris a hydrogen atom, Calkyl optionally having substituent(s), Calkenyl optionally having substituent(s) or amino optionally having substituent(s);'}{'sup': 4a', '4b, 'sub': '1-6', 'Rand Rare the same or different and each is a hydrogen atom, a halogen atom, hydroxy optionally having a substituent or Calkyl optionally having substituent(s);'}{'sup': '5', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl optionally having substituent(s); and'}{'sup': '6', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl optionally having substituent(s).'}33. The compound of claim ...

Подробнее
04-04-2013 дата публикации

CARBOXYLATION CATALYSTS

Номер: US20130085276A1
Принадлежит:

The use of a complex of the form Z—M—OR in the carboxylation of a substrate is described. The group Z is a two-electron donor ligand, M is a metal and OR is selected from the group consisting of OH, alkoxy and aryloxy. The substrate may be carboxylated at a C—H or N—H bond. The metal M may be copper, silver or gold. The two-electron donor ligand may be a phosphine, a carbene or a phosphite ligand. Also described are methods of manufacture of the complexes and methods for preparing isotopically labelled caboxylic acids and carboxylic acid derivatives. 134-. (canceled)25. A method of carboxylation of a substrate , the method comprising;{'sub': '2', 'contacting a complex of the form Z—M—OR ,wherein the group Z is a two-electron donor ligand, M is a metal, and OR is selected from the group consisting of OH, alkoxy and aryloxy; with a substrate and a source of CO.'}26. The method according to claim 25 , wherein the metal M is selected from the group consisting of copper claim 25 , silver and gold.27. The method according to claim 25 , wherein the carboxylation is carried out in the presence of a base.28. The method according to claim 27 , wherein the base is an alkali metal hydroxide or alkoxide.29. The method according to claim 25 , wherein the two-electron donor ligand Z is selected from the group consisting of phosphines claim 25 , carbenes claim 25 , or phosphites.30. The method according to claim 29 , wherein the two-electron donor ligand Z is a nitrogen containing heterocyclic carbene ligand.33. The method according to claim 26 , wherein the complex is selected from the group consisting of: [M(OH)(IMes)] claim 26 , [M(OH)(SIMes)] claim 26 , [M(OH)(IPr)] claim 26 , [M(OH)(ItBu)] claim 26 , and [M(OH)(SIPr)] claim 26 , where M is Au claim 26 , Ag or Cu.34. The method according to claim 25 , wherein the substrate is carboxylated at a C—H or N—H bond.35. The method according to claim 25 , wherein the substrate is a substituted or unsubstituted aromatic compound.36. The ...

Подробнее
11-04-2013 дата публикации

SOLID-PHASE FLUORINATION OF BENZOTHIAZOLES

Номер: US20130089501A1
Принадлежит:

The invention provides a process for the production of an F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I) 18-. (canceled)10. A radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET , which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (I), (Ia), or (Ib) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F;'}{'sup': 18', '−, '(iii) an ion-exchange cartridge for removal of excess F.'}11. A cartridge for a radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (I), (Ia), or (Ib) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F.'}12. A radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET , which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (III) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F.'}13. A cartridge for a radiopharmaceutical kit for the preparation of an F-labelled tracer according to for use in PET which comprises:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, '(i) a vessel containing a compound of formula (III) as defined in ; and'}{'sup': '18', '(ii) means for eluting the vessel with a source of F.'}14. A method for obtaining a diagnostic PET image which comprises the step of using a radiopharmaceutical kit according to or a cartridge for a radiopharmaceutical kit according to . The present invention relates to novel solid-phase processes for the production of radiolabelled tracers, in particular for the production of F-labelled benzothiazole compounds which may be suitable for use as Positron Emission Tomography (PET) radiotracers. The invention also comprises ...

Подробнее
11-04-2013 дата публикации

Compounds Having Activating Effect on Subtypes of Peroxisome Proliferator-Activated Receptors and its Preparation Method and Uses

Номер: US20130089613A1
Принадлежит: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPARα,δ,γ) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPARα,δ,γ). 2. The compound according to claim 1 , wherein X is S claim 1 , O claim 1 , or NR claim 1 , Y is O.3. The compound according to claim 1 , wherein Ris independently H or C-Calkyl.4. The compound according to claim 3 , wherein Ris methyl or H.5. The compound according to claim 4 , wherein Gis selected from C-Calkyl.6. The compound according to claim 5 , wherein Gand Gare each independently selected from H claim 5 , C-Calkyl claim 5 , C-Calkoxy claim 5 , trifluoromethyl claim 5 , F claim 5 , Cl claim 5 , Br claim 5 , nitro claim 5 , NRR claim 5 , C-Calkylthio claim 5 , amido claim 5 , cyano claim 5 , carboxyl and tetrazolyl.7. The compound according to claim 6 , wherein Gis ethyl; G claim 6 , Gare F claim 6 , CFor methyl.9. A pharmaceutical composition claim 1 , comprising the compound according to or pharmaceutical acceptable salts thereof.10. The pharmaceutical composition according to claim 9 , with a dosage form selected from tablets claim 9 , film-coated tablets claim 9 , sugar coated tablets claim 9 , enteric coated tablets claim 9 , dispersible tablets claim 9 , capsules claim 9 , granules claim 9 , oral solutions and oral suspensions.11. Use of a compound according to in the manufacture of a medicament for treating or preventing diseases associated with α subtype claim 1 , δ subtype claim 1 , and γ subtype of peroxisome proliferator-activated receptors.12. The use according to claim 11 , wherein the diseases associated with α subtype claim 11 , δ subtype claim 11 , and γ subtype of peroxisome proliferator-activated receptors are selected from hyperglycaemia claim 11 , insulin resistance claim 11 , hyperlipidemia and obesity.13. Use of ...

Подробнее
11-04-2013 дата публикации

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

Номер: US20130090310A1
Принадлежит: Rigel Pharmaceuticals, Inc.

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds. 2. The compound of claim 1 , wherein Ris H; Ris Calkyl; Ris —OCalkyl; and Ris F.3. The compound of claim 2 , wherein Ris H; Ris CH; Ris —OCH; and Ris F.4. The compound of claim 1 , wherein Ris H; Ris —OCalkyl; Ris —OCalkyl; and Ris H or F.5. The compound of claim 4 , wherein Ris H; Ris —OCalkyl; Ris —OCalkyl; and Ris F.6. The compound of claim 5 , wherein Ris H; Ris —OCH; Ris —OCH; and Ris F.7. The compound of claim 1 , wherein R claim 1 , Rand Rare each independently CH claim 1 , —OCH claim 1 , or F; and Ris H or F.8. The compound of claim 7 , wherein two of R claim 7 , Rand Rare CH; the other of R claim 7 , Rand Ris F; and Ris H or F.9. The compound of claim 7 , wherein two of R claim 7 , Rand Rare CH; the other of R claim 7 , Rand Ris —OCH; and Ris H or F.10. The compound of claim 7 , wherein two of R claim 7 , Rand Rare —OCH; the other of R claim 7 , Rand Ris F; and Ris H or F.11. The compound of claim 7 , wherein two of R claim 7 , Rand Rare —OCH; the other of R claim 7 , Rand Ris CH; and Ris H or F.12. The compound of claim 7 , wherein one of R claim 7 , Rand Ris CH; one of R claim 7 , Rand Ris —OCH; and one of R claim 7 , Rand Ris F; and Ris H or F.14. The compound of claim 13 , wherein Ris H claim 13 , halo or Calkyl.15. The compound of wherein the compound is:I-1: 5-(5-fluoro-4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)-2-methylbenzonitrile formate salt;I-2: 4-(4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)benzamide trifluoroacetate salt;I-3: 3-(4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-ylamino)pyrimidin-2-ylamino)benzamide trifluoroacetate salt;I-4: 5-(5-chloro-2-(phenylamino)pyrimidin-4-ylamino) ...

Подробнее
11-04-2013 дата публикации

Benzoxazole Derivatives Having Inhibitory Activity Against Interleukin-6, Preparation Method Thereof, and Pharmaceutical Composition Containing the Same

Номер: US20130090480A1
Принадлежит:

The present invention relates to benzoxazole derivatives represented by the Formula 1, which has an inhibitory activity against interleukin-6 (IL-6), a method for preparation thereof, and a pharmaceutical composition containing the same. The compound represented by the Formula 1 according to the present invention has a superior inhibitory activity against interleukin-6, and therefore, can be practically applied for prevention and treatment of diseases caused by abnormal interleukin-6 activity. 3. The compound according to characterized in that said Ris phenyl substituted with two identical or different substitutents each independently selected from the group consisting of halogen claim 1 , nitro claim 1 , Chaloalkyl claim 1 , and Calkoxy.4. The compound according to characterized in that said Ris phenyl substituted with halogen and nitro claim 3 , phenyl substituted with halogen and Chaloalkyl claim 3 , phenyl substituted with two halogens claim 3 , or phenyl substituted with two Calkoxy.5. The compound according to characterized in that said Ris phenyl substituted with three Calkoxy.7. The compound according to characterized in that said Ris trifluoromethyl.8. The compound according to characterized in that the compound is selected from the group consisting of:N-(2-(4-ethylphenyl)benzo[d]oxazole-2,5-diamine,N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-2-phenylacetamide,N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)benzamide,4-chloro-N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)benzamide,2-chloro-N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-4-nitrobenzamide,2-chloro-N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-5-nitrobenzamide,3,4-dichlorobenzamide-N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)benzamide,3-(chloromethyl)-N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)benzamide,4-ethyl-N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)benzamide,N-(2-(4-ethylphenylamino)benzo[d]oxazol-5-yl)-3-fluoro-5-(trifluoromethyl)benzamide,2-ethoxy-N-(2-(4-ethylphenylamino)benzo[d] ...

Подробнее
18-04-2013 дата публикации

Raltegravir Salts and Crystalline Forms Thereof

Номер: US20130096147A1
Принадлежит:

The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium. 1. (canceled)2. A crystalline form of Raltegravir potassium selected from:{'figref': [{'@idref': 'DRAWINGS', 'FIG. 2'}, {'@idref': 'DRAWINGS', 'FIG. 31'}], 'sup': 13', '13', '13, 'a) crystalline Form V of Raltegravir potassium, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.0, 11.9, 18.2 and 26.6 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in ; a solid-state C NMR spectrum with signals at 121.9, 144.0, 149.3 and 170.3±0.2 ppm; a solid-state C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 111.9, 134.0, 139.3 and 160.3±0.1 ppm; a solid-state C NMR spectrum substantially as depicted in ; and combinations thereof; and'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, 'b) crystalline Form IV of Raltegravir potassium, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.5, 7.5, 8.1, 18.4 and 23.2 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in ; and combinations thereof.'}3. The crystalline Raltegravir potassium Form V according to claim 2 , characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.0 claim 2 , 11.9 claim 2 , 18.2 and 26.6 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in ; a solid-state C NMR spectrum with signals at 121.9 claim 2 , 144.0 claim 2 , 149.3 and 170.3±0.2 ppm; a solid-state C NMR spectrum having ...

Подробнее
25-04-2013 дата публикации

Process for Producing Imine Compounds for Combating Invertebrate Pests

Номер: US20130102462A1
Принадлежит: BASF SE

The present invention relates to a process for producing aromatic carbonyl compounds of formula I and aromatic imine compounds of formula III 145-. (canceled)48. The process as claimed in claim 46 , where Z is Br claim 46 , I or —OSO—R.49. The process as claimed in claim 48 , where Z is Br claim 48 , I or —OSO—R claim 48 , where Ris selected from the group consisting of CH claim 48 , CFand 4-methylphenyl claim 48 , and is preferably Br.50. The process as claimed in claim 46 , where carbon monoxide and hydrogen are used in a molar ratio of from 20:1 to 1:10.51. The process as claimed in claim 50 , where carbon monoxide and hydrogen are used in a molar ratio of from 2:1 to 1:2 and are preferably used in the form of synthesis gas.52. The process as claimed in claim 46 , where the catalyst is a group VIII metal complex.53. The process as claimed in claim 52 , where the metal is selected from the group consisting of Pd claim 52 , Pt claim 52 , Ni claim 52 , Rh claim 52 , Ir and Ru and is preferably Pd.54. The process as claimed in claim 46 , where the catalyst contains a monodentate and/or bidentate ligand.55. The process as claimed in claim 46 , where the catalyst contains a phosphorus-containing ligand.56. The process as claimed in claim 55 , where the phosphorus-containing ligand is a monodentate ligand selected from the group consisting of phosphorus compounds of formula PRRR claim 55 , where{'sup': a', 'b', 'c', 'd', 'e, 'sub': 3', '12', '3', '12', '3', '10', '3', '10', '5', '18', '5', '18, 'claim-text': or', {'sup': a', 'b', 'e, 'sub': 3', '10, 'Rand Rtogether with the phosphorus atom to which they are bound form a 5-, 6-, 7- or 8-membered heterocyclic ring which may be additionally fused to one, two or three C-C-cycloalkyl, heterocyclyl, aryl or hetaryl groups, where the heterocyclic ring and, if present, the fused-on groups may each independently carry one, two, three or four substituents R;'}, {'sup': d', '1', '2', '1', '2', '3+', '−, 'sub': 3', '10', '3', '10', ...

Подробнее
25-04-2013 дата публикации

PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

Номер: US20130102593A1
Принадлежит:

Described herein are novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease. 2. The compound of claim 1 , wherein Ais an optionally substituted 5 to 7 membered heteroaryl; or a pharmaceutically acceptable salt or solvate thereof.34-. (canceled)5. The compound of claim 1 , wherein Ais an optionally substituted moiety selected form the group consisting of pyridyl claim 1 , thiazolyl claim 1 , oxazolyl claim 1 , imidazolyl claim 1 , pyrazolyl claim 1 , isoxazolyl claim 1 , pyrimidyl claim 1 , oxadiazolyl claim 1 , pyranyl claim 1 , and furanyl; or a pharmaceutically acceptable salt or solvate thereof.6. The compound of claim 1 , wherein Ais an optionally substituted moiety selected form the group consisting thiazolyl claim 1 , oxadiazolyl claim 1 , and oxazolyl; or a pharmaceutically acceptable salt or solvate thereof.717-. (canceled)18. The compound of claim 1 , wherein Lis a bond claim 1 , or an optionally substituted alkylene; or a pharmaceutically acceptable salt or solvate thereof.1923-. (canceled)2533-. (canceled)36. (canceled)37. The compound of claim 1 , wherein Ais an optionally substituted arylene claim 1 , an optionally substituted heteroarylene; or a pharmaceutically acceptable salt or solvate thereof.38. (canceled)4041-. (canceled)42. The compound of claim 39 , wherein Y is —C(R)═; or a pharmaceutically acceptable salt or solvate thereof.4361-. (canceled)63190-. (canceled)195. (canceled)200207-. (canceled)208. A formulation comprising a compound of or a pharmaceutically acceptable salt or solvate thereof claim 1 , and a pharmaceutically acceptable carrier.209. (canceled)210. A method of treating Alzheimer's disease in an individual in need thereof claim 1 , the method comprising administering to the individual an effective amount of a compound of or a pharmaceutically acceptable salt or solvate thereof.211. A method of treating of a condition mediated by memapsin 2 catalytic activity in an individual in ...

Подробнее
02-05-2013 дата публикации

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

Номер: US20130109710A1
Принадлежит: JAPAN TOBACCO INC.

The spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof 3. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 , wherein the number of the double bond in ring A of the spiro-ring AB is 0 or 1.4. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 , wherein the number of the double bond in ring B of the spiro-ring AB is 0 or 1.5. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 , wherein n3 is 1 or 2.6. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed claim 1 , wherein the spiro-ring AB may be substituted by 1 to 3 same or different substituent(s).7. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 ,{'sup': '1', 'wherein Ris'}(1) a hydrogen atom,{'sub': 1', '6, '(2) a C-Calkyl group,'}{'sub': 2', '6, '(3) a C-Calkenyl group,'}{'sub': 2', '6, '(4) a C-Calkynyl group,'}{'sub': 1', '6, '(5) a C-Calkoxy group,'}{'sub': 1', '6', '1', '6, '(6) a C-Calkoxy(C-C)alkyl group,'}{'sup': 11', '12', '11', '12, 'sub': 1', '6, '(7) —CONRRin which Rand Rare the same or different and each represents a hydrogen atom or a C-Calkyl group, or'}{'sub': 1', '6, '(8) a five-membered heteroaryl group which has at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, and which may be substituted by a C-Calkyl group.'}8. The spiro compound claim 1 , the pharmaceutically acceptable salt thereof or the solvate thereof as claimed in claim 1 ,{'sup': '1', 'wherein Ris'}(1) a hydrogen atom,{'sub': 2', '6, '(2) a C-Calkenyl group,'}{'sub': 2', '6, '(3) a C-Calkynyl group,'}{'sub': 1', '6, '(4) a C-Calkoxy group or'}{'sub': 1', '6, '(5) a five- ...

Подробнее
16-05-2013 дата публикации

TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS

Номер: US20130123217A1
Принадлежит: NEUMEDICS

The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity because of their inhibition of neuronal cell cycle progression. The compounds are characterized in part by a fifth ring joining positions 9 and 10. 2. The compound of claim 1 , where Ris NH(CH)OH.3. The compound of claim 2 , where the compound is an up epimer at R.4. The compound of claim 1 , where Ris disubstituted.5. The compound of claim 4 , where one Rsubstitution is N(CH)and the other substitution is an alkyl.6. The compound of claim 1 , where Ris a substitutent that reduces antibiotic potency.7. The compound of claim 1 , where R″ at Ris benzyl or phenyl.8. The compound of claim 1 , where Rand Rtaken together form a 2 to 5 membered ring of the formula O—Y—HN— claim 1 , and where Y is CH or CO.9. The compound of claim 1 , where Rcontains nitrogen.10. The compound of claim 1 , where Ris a capped phenolic O.11. A method of ameliorating a neurodegenerative disease claim 1 , comprising the step of administering to a subject in need thereof a composition comprising a therapeutically effective amount of a compound of .12. The method of claim 11 , wherein the composition inhibits neuronal cell cycle progression before entry of a neuronal cell into a synthesis (S) phase.13. The therapeutic method of claim 11 , wherein the composition inhibits neuronal cell cycle progression at or prior to the early growth (G 1) phase.14. The method of claim 11 , further comprising the administration of a secondary agent selected from the group consisting of acetylsalicylic acid claim 11 , any salicylate which inhibits early phase cell cycle progression claim 11 , sirolimus claim 11 , any sirolimus ...

Подробнее
23-05-2013 дата публикации

Heterocyclic Compound and Light-Emitting Element, Light-Emitting Device, Lighting Device, and Electronic Device Using the Same

Номер: US20130130061A1
Принадлежит: Semiconductor Energy Laboratory Co Ltd

To provide a novel heterocyclic compound having a bipolar property. To improve element characteristics of a light-emitting element by application of the novel heterocyclic compound to the light-emitting element. A heterocyclic compound represented by a general formula (G1) and a light-emitting element formed using the heterocyclic compound represented by the general formula (G1) are provided. When the heterocyclic compound represented by the general formula (G1) is used for the light-emitting element, the characteristics of the light-emitting element can be improved.

Подробнее
23-05-2013 дата публикации

SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF

Номер: US20130131044A1
Принадлежит:

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. 2. The compound of wherein said non-interfering substituent is selected from one or more of the group consisting of alkyl claim 1 , cycloalkyl claim 1 , alkenyl claim 1 , cycloalkenyl claim 1 , alkynyl claim 1 , aryl claim 1 , heteroaryl claim 1 , arylalkyl claim 1 , heteroarylalkyl claim 1 , arylalkenyl claim 1 , heteroarylalkenyl claim 1 , arylalkynyl claim 1 , and heteroarylalkynyl claim 1 , each of which may be optionally substituted with one or more heteroatoms or additional non-interfering substituents.36-. (canceled)89-. (canceled)10. The compound of wherein the compound is selected from the following group:rac-(3aR,4R,5R,6R,7aS)-2-amino-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(ethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-(propylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(butylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(allylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-((4-methoxybenzyl)amino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(dimethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(ethyl(methyl)amino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;(3aR,4R,5R,6R,7aS)-2-amino-6-(hydroxymethyl)-3a,4,5,6,7 ...

Подробнее
23-05-2013 дата публикации

Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners

Номер: US20130131063A1
Принадлежит: INFINITY PHARMACEUTICALS, INC.

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer. 138-. (canceled)40. The method of claim 39 , wherein the bcl-mediated disorder is cancer or neoplastic disease.41. The method of claim 39 , wherein the bcl-mediated disorder is cancer.42. The method of claim 39 , wherein the bcl-mediated disorder is neoplastic disease.43. The method of claim 39 , wherein the bcl-mediated disorder is selected from the group consisting of acute leukemia claim 39 , acute lymphocytic leukemia claim 39 , acute myelocytic leukemia claim 39 , myeloblastic claim 39 , promyelocytic claim 39 , myelomonocytic claim 39 , monocytic claim 39 , erythroleukemia claim 39 , chronic leukemia claim 39 , chronic myelocytic (granulocytic) leukemia claim 39 , chronic lymphocytic leukemia claim 39 , polycythemia vera claim 39 , Hodgkin's disease claim 39 , non-Hodgkin's disease; multiple myeloma claim 39 , Waldenstrom's macroglobulinemia claim 39 , heavy chain disease claim 39 , fibrosarcoma claim 39 , myxosarcoma claim 39 , liposarcoma claim 39 , chondrosarcoma claim 39 , osteogenic sarcoma claim 39 , chordoma claim 39 , angiosarcoma claim 39 , endotheliosarcoma claim 39 , lymphangiosarcoma claim 39 , lymphangioendotheliosarcoma claim 39 , synovioma claim 39 , mesothelioma claim 39 , Ewing's tumor claim 39 , leiomyosarcoma claim 39 , rhabdomyosarcoma claim 39 , colon carcinoma claim 39 , pancreatic cancer claim 39 , breast cancer claim 39 , ovarian cancer claim 39 , prostate cancer claim 39 , squamous cell carcinoma claim 39 , basal cell carcinoma claim 39 , adenocarcinoma claim 39 , sweat gland carcinoma claim 39 , sebaceous gland carcinoma claim 39 , papillary carcinoma claim 39 , papillary adenocarcinomas claim 39 , stadenocarcinoma claim 39 , medullary carcinoma claim 39 , bronchogenic carcinoma claim 39 , renal cell carcinoma ...

Подробнее
23-05-2013 дата публикации

USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER

Номер: US20130131084A1

The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: 120-. (canceled)24. The method according to claim 21 , wherein{'sub': '4', 'Rrepresents a nitrile or a carboxamide group, and'}{'sub': 5', '7, 'Rand Rrepresent a hydrogen atom.'}28. The method according to or claim 21 , wherein the compound of formula (I) or (II) is such that R claim 21 , Rand Rrepresent a hydrogen atom.29. The method according to or claim 21 , wherein the compound of formula (I) or (II) is such that Ris not a hydrogen atom.30. The method according to or claim 21 , wherein the compound of formula (I) or (II) is such that Ris not a hydrogen atom.31. The method according to anyone of or claim 21 , wherein said compound is selected fro the group consisting of:(Z)-2-(5-methoxy-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(5-ethoxy-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(5-isopropoxy-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(5-chloro-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(5-fluoro-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(4-methoxy-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-3-(6-fluoropyridin-3-yl)-2-(5-methoxy-1H-indol-3-yl)-acrylonitrile;(Z)-2-(6-methoxy-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(1H-indol-3-yl)-3-pyrimidin-5-yl-acrylonitrile;(Z)-2-(5-methoxy-1H-indol-3-yl)-3-pyrimidin-5-yl-acrylonitrile;(Z)-3-(1-cyano-2-(pyridin-3-yl)vinyl)-1H-indol-5-yl-acetate;(Z)-3-(1-cyano-2-(pyridin-3-yl)vinyl)-1H-indol-5-yl 2-methoxyacetate;(Z)-2-(5-benzyloxy-1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-2-(1H-indol-3-yl)-3-pyridin-3-yl-acrylonitrile;(Z)-3-(3,5-dimethoxy-phenyl)-2-(5-methoxy-1H-indol-3-yl)-acrylonitrile;(Z)-3-(3,5-dimethoxy-phenyl)-2-(1H-indol-3-yl)-acrylonitrile;(Z)-3-(4-chloro-phenyl)-2-(1H-indol-3-yl)-acrylonitrile;(Z)-2-(5-methoxy-1H-indol-3-yl)-3-pyridin-3-yl-propionitrile;(Z)-3-benzo[1,3]dioxol-5-yl-2-(1H-indol-3-yl)-acrylonitrile;(Z)-3-(1H-indol-3-yl)-2-pyridin-3-yl- ...

Подробнее
23-05-2013 дата публикации

CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF

Номер: US20130131085A1
Принадлежит: ABBOTT LABORATORIES

The present invention features compounds of formula I 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate or prodrug thereof claim 1 , wherein said compound is selected from the group consisting of:tert-butyl(1S,3S,4S)-3-hydroxy-5-phenyl-1-(4-pyridin-2-ylbenzyl)-4-{[(1,3-thiazol-5-ylmethoxy) carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-4-(acetylamino)-1-benzyl-2-hydroxy-5-phenylpentyl carbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-4-amino-1-benzyl-2-hydroxy-5-phenylpentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-2-hydroxy-4-[(methylsulfonyl)amino]-5-phenyl pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-4-{[(dimethylamino)carbonyl]amino}-2-hydroxy-5-phenylpentylcarbamate;methyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-4-{[(dimethylamino)sulfonyl]amino}-2-hydroxy-5-phenylpentylcarbamate;tert-butyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;isobutyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;isopropyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;tert-butyl (1S,3R,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-4-ylmethyl (1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-4-ylmethoxy)carbonyl]amino}pentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-2-hydroxy-4-{[(2-isopropyl-1,3-thiazol-4-yl)acetyl]amino}-5-phenylpentylcarbamate;1,3-thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-4-{[(tert-butylamino)carbonyl]amino}-2-hydroxy-5-phenylpentylcarbamate;tert-butyl benzyl((2R,3S)-2-hydroxy-4-phenyl-3-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}butyl)carbamate;1,3- ...

Подробнее
23-05-2013 дата публикации

BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS

Номер: US20130131109A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions. 162-. (canceled)65. (canceled)66. (canceled)68. (canceled)69. The method according to claim 67 , wherein the disease claim 67 , condition claim 67 , or disorder is implicated in the activation or hyperactivity of voltage-gated sodium channels.70. The method according to claim 67 , wherein the disease claim 67 , condition claim 67 , or disorder is radicular pain claim 67 , sciatica claim 67 , back pain claim 67 , head pain claim 67 , neck pain claim 67 , or neuropathies.71. The method according to claim 69 , wherein the disease claim 69 , condition claim 69 , or disorder is severe or intractable pain claim 69 , acute pain claim 69 , post-surgical pain claim 69 , back pain claim 69 , or cancer pain.72. The method according to claim 67 , wherein the disease claim 67 , condition claim 67 , or disorder is implicated in the activation or hyperactivity of voltage-gated calcium channels.73. The method according to claim 72 , wherein the disease claim 72 , condition claim 72 , or disorder is acute claim 72 , chronic claim 72 , neuropathic claim 72 , inflammatory pain claim 72 , or inflammatory breakthrough pain. The present application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Application No. 60/715,980, filed Sep. 9, 2005, the entire contents of the above application being incorporated herein by reference.The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Na channels are central to the generation of action potentials in all excitable cells such as neurons and myocytes. They play key roles in excitable tissue including brain, smooth muscles of the gastrointestinal tract, skeletal ...

Подробнее
30-05-2013 дата публикации

Polymorphs of an Active Pharmaceutical Ingredient

Номер: US20130137734A1
Принадлежит: SANDOZ AG

The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions camprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat. 115-. (canceled)16. A crystalline form of Febuxostat having an X-ray powder diffraction pattern as measured using CuKα radiation comprising peaks at 2-theta angles of 6.6±0.2° , 12.8±0.2° , 24.5±0.2 , 25.8±0.2° , 26.6±0.2°.17. The crystalline form of Feboxostat according to characterized by an IR spectrum comprising absorption bands at wavenumbers of about 2960±2 cm claim 16 , 2874±2 cm claim 16 , 2535±2 cm claim 16 , 2229±2 cm claim 16 , 1673±2 cm claim 16 , 1605±2 cm claim 16 , 1509±2 cm claim 16 , 1422±2 cm claim 16 , 1368±2 cm claim 16 , 1323±2 cm claim 16 , 1274±2 cm claim 16 , 1166±2 cm claim 16 , 1116±2 cm claim 16 , 1045±2 cm claim 16 , 1013±2 cm claim 16 , 911±2 cm claim 16 , 820±2 cm claim 16 , 763±2 cmand 725±2 cm.18. The crystalline form of Febuxostat according to characterized by a moisture sorption/desorption curve as shown in .19. A pharmaceutical composition comprising a crystalline form of Febuxostat according to claim 16 , further comprising at least one pharmaceutically acceptable excipient.20. The pharmaceutical composition according to claim 19 , which is an oral dosage form preferably a capsule or a tablet.21. A process for the production of a pharmaceutical composition according to claim 19 , comprising the step of mixing a crystalline form of Febuxostat according to with a pharmaceutically acceptable excipient.22. A crystalline form of Febuxostat characterized by an X-ray powder diffraction pattern as measured using CuKα radiation comprising peaks at 2-theta angles of 2.9±0.2° claim 19 , 5.8±0.2° claim 19 ...

Подробнее
30-05-2013 дата публикации

PROCESS FOR THE PREPARATION OF LINEZOLID

Номер: US20130137864A1
Принадлежит:

The present invention provides an improved process for the preparation of Linezolid of formula (D. The present invention relates to preparation of intermediate (R)—N-[[3-[3-fluoro-4-morpholinyl]phenyl|-2-oxo-5-oxazolidinyl]methanol of formula (II), Linezolid amine of formula (Ia) and their use in the preparation of Linezolid. The present invention further provides process for the preparation of Form I of Linezolid of formula (I). 3. The method of or , wherein said suitable solvent is tetrahydrofuran.4. (canceled)7. The method of or , wherein said acylating agent is acetic anhydride or acetyl chloride.8. The method of or , wherein said ketonic solvent is acetone , methyl iso-butyl ketone , methyl ethyl ketone , or a mixture thereof.9. The method of claim 6 , wherein said crystallization is carried out in n-propanol or methyl iso-butyl ketone.10. A Linezolid of formula (I) obtained by the method of or claim 6 , having content of (R)-enantiomer less than about 0.1% and content of bis-Linezolid less than about 0.15%.11. A Linezolid of formula (I) obtained by the method of or claim 6 , having purity greater than 99%. The present invention provides an improved process for the preparation of Linezolid of formula (I).The present invention relates to preparation of intermediate (R)—N—[[3-[3-fluoro-4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methanol of formula (II), Linezolid amine of formula (Ia) and their use in the preparation of Linezolid.The present invention further provides process for the preparation of Form I of Linezolid of formula (I).Linezolid is chemically known as N—[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide and marketed by Pfizer in US under brand name Zyvox. Linezolid is a synthetic antibacterial agent of the oxazolidinone class. It is used for the treatment of infections caused by multi-resistant bacteria including streptococci and methicillin-resistantLinezolid was first disclosed in U.S. Pat. No. 5,688,792. The process ...

Подробнее
06-06-2013 дата публикации

COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM

Номер: US20130143927A1
Принадлежит: CalciMedica, Inc.

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. 4. The compound of wherein aryl is substituted with at least one Rselected from Cl claim 3 , Br claim 3 , F claim 3 , I claim 3 , CF claim 3 , C-Calkyl claim 3 , or OC-Calkyl.5. The compound of wherein aryl is substituted with at least one Rselected from Cl claim 3 , Br claim 3 , F claim 3 , and I.6. The compound of wherein Ris methyl.7. The compound of wherein Ris heteroaryl substituted with at least one R.8. The compound of wherein heteroaryl is selected from pyridyl claim 7 , pyrimidyl claim 7 , pyridazinyl claim 7 , pyrazinyl claim 7 , thienyl claim 7 , furyl claim 7 , pyranyl claim 7 , thiadiazolyl claim 7 , pyrazolyl claim 7 , imidazolyl claim 7 , thiazolyl claim 7 , isothiazolyl claim 7 , oxazolyl claim 7 , isoxazolyl claim 7 , indolyl claim 7 , indazolyl claim 7 , benzoxazolyl claim 7 , benzoisoxazolyl claim 7 , benzothiazolyl claim 7 , benzoisothiazolyl claim 7 , benzimidazolyl claim 7 , quinolyl claim 7 , pteridinyl claim 7 , pyrazolopyridinyl claim 7 , pyrazolopyrimidinyl claim 7 , imidazolothiazolyl claim 7 , quinoxazinyl claim 7 , and indolizinyl.9. The compound of wherein heteroaryl is pyridyl.10. The compound of wherein heteroaryl is substituted with at least one Rselected from Cl claim 8 , Br claim 8 , F claim 8 , and I.15. A pharmaceutical composition comprising a pharmaceutically acceptable diluent claim 1 , excipient claim 1 , or binder claim 1 , and a compound of or a pharmaceutically acceptable salt claim 1 , pharmaceutically acceptable prodrug claim 1 , or pharmaceutically acceptable solvate thereof.16. A method for treating a disease claim 1 , disorder or condition in a ...

Подробнее
13-06-2013 дата публикации

PROCESS FOR THE MANUFACTURE OF CHIRAL CATALYSTS AND THEIR SALTS

Номер: US20130150574A1
Принадлежит: ScinoPharm Taiwan, Ltd.

The present invention provides efficient and economical methods for synthesis of (−)-2-exo-morpholinoisoborne-10-thiol, its enantiomer, and related chiral catalysts. Novel compounds and methods of asymmetric synthesis are also disclosed. 2. A process according to claim 1 , wherein the first reducing agent is an aluminum hydride reagent.3. A process according to claim 2 , wherein the aluminum hydride reagent is sodium bis(2-methoxyethoxy)aluminum hydride.4. A process according to claim 1 , wherein the second reducing agent is selected from the group consisting of a metal including zerovalent metals claim 1 , zerovalent metal alloys claim 1 , and non-zerovalent metals claim 1 , a metal hydride and a highly reactive thiol.5. A process according to claim 1 , wherein R claim 1 , R claim 1 , and N together form a morpholine group.8. A process according to claim 7 , wherein the compound of formula (Is) is the exo-diastereomer.9. A process according to claim 7 , wherein the acid is HCl.11. A compound according to claim 10 , wherein HX is HCl.1716. A method of asymmetric synthesis comprising contacting a compound according to any one of - with reactants in an asymmetric transformation to stereoselectively provide a product.18. The method according to claim 17 , wherein the asymmetric transformation is an asymmetric addition reaction. This application claims the benefit of priority to U.S. Provisional Application Ser. No. 61/565,449, filed Nov. 30, 2011, the entire content of which is incorporated herein by reference.NOT APPLICABLENOT APPLICABLE((−)-2-exo-morpholinoisoborne-10-thiol, abbreviated as “(−)-MITH” and classified as a γ-aminothiol ligand, is an efficient catalyst that induces the stereoselective formation of chiral carbon centers in certain reactions (2006, 71, 833-835). (−)-MITH (CAS No. 874896-16-9) has the systematic name ((1R,2R,4R)-7,7-dimethyl-2-morpholino-bicyclo[2.2.1]heptan-1-yl)methanethiol and the structure:The abbreviation MITH is used herein to apply ...

Подробнее
13-06-2013 дата публикации

NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS

Номер: US20130150579A1
Принадлежит: RANBAXY LABORATORIES LIMITED

The present invention provides a process for preparing novel intermediates of Formula wherein, Rcan be hydrogen, C-Calkyl, halogen, nitro, hydroxy, or C-Calkoxy; Rcan be selected from hydrophobic residue of HMG-CoA reductase inhibitors; which can be effectively used for the preparation of HMG-CoA reductase inhibitors such as rosuvastatin and pharmaceutically acceptable salts thereof. 4. Use of an intermediate of Formula IVa or Formula Va for preparing rosuvastatin or pharmaceutically acceptable salts thereof.6. The process according to claim 5 , wherein ‘L’ is leaving group selected from a group consisting of alkyl sulphonyloxy claim 5 , aryl suphonyloxy claim 5 , phosphate or phosphite groups.7. The process according to claim 6 , wherein ‘L’ is diphenyl phosphate.8. The process according to claim 5 , wherein Ris C-Calkyl.9. The process according to claim 5 , wherein the step (b) is reacted in the presence of a base selected from triethylamine claim 5 , diisopropylethylamine claim 5 , diisopropylamine claim 5 , pyridine or dimethylaminopyridine.10. The process according to claim 9 , wherein an organic base is diisopropylethylamine.11. The process according to claim 5 , wherein the step (c) is performed using an oxidizing agent selected from a group consisting of permanganates claim 5 , meta-chloro per benzoic acid claim 5 , sodium hypochlorite claim 5 , hydrogen peroxide claim 5 , tert-butyl hydrogen peroxide claim 5 , cumene hydroperoxide or oxone (2KHSO.KHSO.KSO) in the presence of transition metal catalysts.12. The process according to claim 11 , wherein oxidation is performed using hydrogen peroxide in the presence of ammonium molybdate.13. The process according to claim 5 , wherein Pand Pare acetonide (isopropylidene) group.14. The process according to claim 5 , wherein an amine salt is selected from a group consisting of methyl amine claim 5 , ethyl amine claim 5 , n-propyl amine claim 5 , isopropyl amine claim 5 , n-butyl amine or tert-butyl amine.15. The ...

Подробнее
13-06-2013 дата публикации

Process for the Preparation of Esomeprazole Magnesium Dihydrate

Номер: US20130150587A1
Принадлежит: CIPLA LIMITED

A process for preparing Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium dihydrate, processes for preparing various intermediates useful in the preparation of Form A of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium dihydrate and a novel polymorphic Form II of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole. 1. Form II of 5-methoxy-2-[[(4-methoxy-3 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole having an XRPD pattern with ° 2θ values at 20.7 , 20.9 and 25.6±0.2° 2θ.2. Form II of 5-methoxy-2-[[(4-methoxy-3 claim 1 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole according to claim 1 , having the XRPD pattern as shown in .3. A process for preparing Form II of 5-methoxy-2-[[(4-methoxy-3 claim 1 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole comprising crystallising or recrystallising crude 5-methoxy-2-[[(4-methoxy-3 claim 1 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole from ethyl acetate at a temperature ranging from 50 to 60° C. claim 1 , cooling and isolating the Form II of 5-methoxy-2-[[(4-methoxy-3 claim 1 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole.4. The process according to claim 3 , wherein the cooling is to a temperature ranging from −10 to −5° C.5. The process according to claim 3 , wherein the isolation comprises filtration followed by washing with ethyl acetate.6. The process according to claim 3 , wherein the crude 5-methoxy-2-[[(4-methoxy-3 claim 3 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole is extracted with methylene dichloride before recrystallisation.7. The process according to claim 6 , wherein the washed Form II of 5-methoxy-2-[[(4-methoxy-3 claim 6 ,5-dimethyl-2-pyridinyl)-methyl]thio]-1H-benzimidazole is dried at a temperature ranging from 30 to 35° C.8. The process according to claim 3 , wherein the crude 5-methoxy-2-[[(4-methoxy-3 claim 3 ,5-dimethyl- ...

Подробнее
20-06-2013 дата публикации

Compounds, Compositions and Methods Related to PPAR Antagonists

Номер: US20130158063A1
Принадлежит: GEORGETOWN UNIVERSITY

Disclosed are compounds, compositions and methods related PPAR antagonists. Certain compounds are effective at inhibiting PPARs. The compositions can be used to inhibit PPARs, treat cancer and treat metabolic disorders. 214-. (canceled)1720-. (canceled)2440-. (canceled)42. The method of claim 23 , wherein the PPAR is PPARγ.44. The method of claim 43 , wherein the composition induces estrogen receptor alpha (ERα) expression in cancer cells.45. The method of claim 44 , wherein the cancer cells are ERα negative.46. The method of claim 44 , wherein the ERα expression results in ERα dependent cancer cells.47. The method of claim 46 , wherein the ERα dependent cancer cells are responsive to anti-estrogen therapy.48. The method of further comprising administering an anti-estrogen therapy.50. The method of claim 49 , wherein the metabolic disorder is dislipidemia or diabetes.53. The method of claim 51 , wherein the PPAR-mediated disease or condition is a PPARγ-mediated disease or condition claim 51 , wherein the disease or condition is selected from the group consisting of diabetes claim 51 , obesity claim 51 , metabolic syndrome claim 51 , impaired glucose tolerance claim 51 , syndrome X claim 51 , and cardiovascular disease claim 51 , or both.54. (canceled)55. The method of claim 51 , wherein the disease or condition is selected from the group consisting of diabetes and cardiovascular disease.57. The compound of claim 56 , wherein Ris pyrazolidine-3 claim 56 ,5 claim 56 ,dione claim 56 , 2-thioxothiazolidin-4-1 claim 56 , 2-thioxooxazolidin-4-1 claim 56 , thiazolidine-2 claim 56 ,4-dione or 5-thioxopyrazolidin-3-1 claim 56 , Ris phenyl claim 56 , ethyl claim 56 , butyl claim 56 , cyclohexyl claim 56 , biphenyl claim 56 , phenoxybenzyl propyl 1-methylcyclopropanecarboxylate or halogenated benzene claim 56 , Ris O claim 56 , S claim 56 , or NH claim 56 , Ris CH and Ris CH claim 56 , Ris —SO— claim 56 , —NH— or —S(O)NH— claim 56 , and Ris H claim 56 , C-Calkyl claim 56 , ...

Подробнее
20-06-2013 дата публикации

METAXALONE COCRYSTALS

Номер: US20130158083A1
Принадлежит:

The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalone adipic acid cocrystal, a 1:0.5 metaxalone fumaric acid cocrystal, a 1:1 metaxalone salicyclic acid cocrystal, a 1:0.5 metaxalone succinic acid cocrystal, and a 1:0.5 metaxalone maleic acid cocrystal. The therapeutic uses of these metaxalone cocrystals are described as well as therapeutic compositions containing them. 1. A metaxalone cocrystal selected from a 1:1 metaxalone adipic acid cocrystal , a 1:0.5 metaxalone fumaric acid cocrystal , a 1:1 metaxalone salicyclic acid cocrystal , a 1:0.5 metaxalone succinic acid cocrystal , and a 1:0.5 metaxalone maleic acid cocrystal.2. A metaxalone cocrystal of claim 1 , wherein the cocrystal is a 1:1 metaxalone adipic acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 8.5 claim 1 , 15.8 claim 1 , 18.9 claim 1 , 20.2 claim 1 , and 23.6 °2θ±0.2°2θ.3. A metaxalone cocrystal of claim 1 , wherein the cocrystal is a 1:1 metaxalone adipic acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 8.5 claim 1 , 15.8 claim 1 , 18.9 claim 1 , 20.2 claim 1 , and 23.6 °2θ±0.2°2θ claim 1 , or by a powder X-ray diffraction pattern substantially similar to .4. A metaxalone cocrystal of claim 1 , wherein the cocrystal is a 1:0.5 metaxalone fumaric acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 5.6 claim 1 , 11.0 claim 1 , 13.1 claim 1 , 18.3 claim 1 , 21.6 claim 1 , and 22.7 °2θ±0.2°2θ.5. A metaxalone cocrystal of claim 1 , wherein the cocrystal is a 1:0.5 metaxalone fumaric acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 5.6 claim 1 , 11.0 claim 1 , 13.1 claim 1 , 18.3 claim 1 , 21.6 claim 1 , and 22.7 °2θ±0.2°2θ claim 1 , or by a powder X-ray ...

Подробнее
27-06-2013 дата публикации

PREPARATION OF FEBUXOSTAT

Номер: US20130165662A1
Принадлежит:

Processes for preparing febuxostat. 2. The process of claim 1 , wherein a reaction medium comprises a Cto Clinear or branched chain alcohol.3. The process of claim 1 , wherein a reaction medium comprises isopropanol.4. The process of claim 1 , wherein a solid compound of Formula II is separated without cooling a reaction mass.5. The process of claim 1 , wherein a solid compound of Formula II is separated at about 30° C. to about 60° C.6. A process for purifying ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate by recrystallizing claim 1 , slurrying claim 1 , or both in a solvent comprising chloroacetyl chloride claim 1 , formic acid claim 1 , or ethyl 2-chloroacetoacetate.7. The process of claim 6 , wherein a solvent for purification comprises chloroacetyl chloride.8. Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate having a purity at least 99 percent by weight.10. A process for preparing febuxostat claim 6 , comprising hydrolyzing ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate in the presence of a ketone solvent.11. The process of claim 10 , wherein a ketone solvent comprises acetone claim 10 , ethyl methyl ketone claim 10 , or methyl isobutyl ketone.12. The process of claim 10 , wherein a ketone solvent is acetone.13. The process of claim 10 , wherein hydrolyzing comprises reacting with lithium hydroxide.14. The process of claim 13 , wherein lithium hydroxide is used in the form of an aqueous solution.15. A process for the preparation of crystalline Form III of febuxostat claim 13 , comprising recrystallizing febuxostat from a solution in a combination of an ester solvent and a hydrocarbon solvent.16. The process of claim 15 , wherein an ester solvent comprises ethyl acetate claim 15 , n-propyl acetate claim 15 , isopropyl acetate claim 15 , n-butyl acetate claim 15 , or tertiary-butyl acetate.17. The process of claim 15 , wherein a hydrocarbon solvent comprises toluene claim 15 , xylene claim 15 , n-hexane ...

Подробнее
04-07-2013 дата публикации

NOVEL SOLID FORMS

Номер: US20130172329A1
Принадлежит: Hoffmann-La Roche Inc.

The instant invention relates to novel solid forms of the compound of formula (I) 2. The compound of claim 1 , comprising crystalline (1 claim 1 ,1-dioxo-1λ-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone monohydrate in polymorphic form B claim 1 , having an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta of approximately 13.3° claim 1 , 20.6° claim 1 , 22.5°.3. The compound of claim 2 , comprising crystalline polymorphic form B claim 2 , having the XRPD diffraction pattern of .4. The compound of claim 1 , comprising crystalline polymorphic form B claim 1 , having the FTIR spectrum of .5. The compound of claim 1 , comprising crystalline polymorphic form B having the Raman spectrum of .6. The compound of claim 1 , comprising crystalline 1 claim 1 ,1-dioxo-1λ-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone in anhydrous polymorphic form C claim 1 , having an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta of approximately 17.4° claim 1 , 23.4°.7. The compound of claim 1 , having crystalline polymorphic form C claim 1 , having the XRPD diffraction pattern of .8. The compound of claim 1 , comprising crystalline polymorphic form C claim 1 , having the FTIR spectrum of .9. The compound of claim 1 , comprising crystalline polymorphic form C claim 1 , having the Raman spectrum of .10. The compound of claim 1 , comprising crystalline (1 claim 1 ,1-dioxo-1λ-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone trifluoroethanol mono-solvate in polymorphic form D claim 1 , having an XRPD diffraction pattern comprising XRPD peaks at angles of diffraction 2Theta of approximately 6.1° claim 1 , 16.8° claim 1 , 22.6°.11. The compound of claim 1 , comprising crystalline polymorphic form D claim 1 , having the XRPD diffraction pattern of .12. The compound of claim 1 , comprising ...

Подробнее
04-07-2013 дата публикации

2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS

Номер: US20130172335A1
Принадлежит: Hoffmann-La Roche Inc.

The present invention relates to compounds of formula I 2. A compound according to claim 1 , wherein A is C—R.3. A compound according to claim 1 , wherein one of Rand Ris selected from the group consisting of:{'sub': 1-7', '1-7', '1-7', '1-7', '1-7, 'phenyl, said phenyl being substituted by a group selected from carboxyl, carboxyl-C-alkyl, carboxyl-C-alkoxy, C-alkoxycarbonyl, C-alkoxycarbonyl-C-alkyl,'}{'sub': 1-7', '1-7', '1-7', '1-7', '1-7', '1-7, 'C-alkoxycarbonyl-C-alkoxy and aminocarbonyl, and, in addition, optionally substituted by one or two substituents selected from the group consisting of C-alkyl, halogen, halogen-C-alkyl, C-alkoxy and halogen-C-alkoxy;'}{'sub': 1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7, 'phenyloxy, wherein the phenyl ring is unsubstituted or substituted by one, two or three substituents selected from the group consisting of C-alkyl, halogen, halogen-C-alkyl, C-alkoxy, halogen-C-alkoxy; carboxyl, carboxyl-C-alkyl, carboxyl-C-alkoxy, C-alkoxycarbonyl, C-alkoxycarbonyl-C-alkyl, C-alkoxycarbonyl-C-alkoxy and aminocarbonyl, heteroaryl selected from the group consisting of pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, said heteroaryl being unsubstituted or substituted by one, two or three substituents selected from the group consisting of C-alkyl, halogen, halogen-C-alkyl, C-alkoxy, halogen-C-alkoxy, carboxyl, carboxyl-C-alkyl, carboxyl-C-alkoxy, C-alkoxycarbonyl, C-alkoxycarbonyl-C-alkyl, C-alkoxycarbonyl-'}{'sub': '1-7', 'C-alkoxy and aminocarbonyl;'}{'sub': 1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7', '1-7, 'heteroaryloxy, wherein heteroaryl is selected from the group consisting of pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and is unsubstituted or substituted by one, two or three substituents selected from the group consisting of C-alkyl, halogen, halogen-C-alkyl, C-alkoxy, halogen-C-alkoxy; carboxyl, ...

Подробнее
04-07-2013 дата публикации

SULFONAMIDE COMPOUNDS

Номер: US20130172339A1
Принадлежит: KANCERA AB

A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer. 119-. (canceled)21. The compound of claim 20 , wherein A is O or S; or a pharmaceutically acceptable salt claim 20 , hydrate claim 20 , solvate claim 20 , or N-oxide thereof.22. The compound of claim 21 , wherein A is S; or a pharmaceutically acceptable salt claim 21 , hydrate claim 21 , solvate claim 21 , or N-oxide thereof.23. The compound of claim 21 , wherein{'sup': '1', 'Ris selected from H; halogen; and C1-C6 alkyl optionally substituted with at least one halogen; and'}{'sup': 2', '3', '6', '6, 'Rand Rform, together with the carbon atoms to which they are attached, a benzene ring, optionally substituted with at least one R; or a 5- or 6-membered heteroaromatic or heterocyclic ring, optionally substituted with at least one R; or'}{'sup': 1', '2', '6', '6, 'Rand Rform, together with the carbon atoms to which they are attached, a benzene ring optionally substituted with at least one R; or a 5- or 6-membered heteroaromatic or heterocyclic ring, optionally substituted with at least one R; and'}{'sup': '3', 'Ris selected from H; halogen; C1-C6 alkyl optionally substituted with at least one halogen;'}or a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof.24. The compound of claim 21 , wherein{'sup': '1', 'Ris selected from H; halogen; and C1-C6 alkyl optionally substituted with at least one halogen;'}{'sup': 2', '3', '6', '6', '6, 'claim-text': [{'sup': 2', '3, 'at least one of Rand Ris selected from said phenyl, heteroaryl, arylsulfonyl and heteroarylsulfonyl, and'}, {'sup': 2', '3, 'when L is (a), neither Rnor Ris unsubstituted phenyl;'}], 'Rand Rare independently selected from H; halogen; C1-C6 alkyl optionally substituted with at least one halogen; phenyl optionally substituted with at least one R; 5- or 6-membered heteroaryl optionally substituted with at ...

Подробнее
04-07-2013 дата публикации

1-ACYL-4-(PHENOXY, BENZYLOXY, OR PHENYLAMINO)-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES

Номер: US20130172345A1
Принадлежит: KOWA COMPANY, LTD.

Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); 1. A tetrahydroquinoline compound , a salt of the compound , a solvate of the compound , or a solvate of the salt , wherein the tetrahydroquinoline compound is selected from the group consisting of the following compounds:1-acetyl-8-fluoro-4-[(2-fluorophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (4)];1-cyclohexanecarbonyl-6-fluoro-4-[(4-fluorophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (6)];1-acetyl-7-cyano-2-methyl-4-phenylamino-1,2,3,4-tetrahydroquinoline [Compound (7)];1-acetyl-6-cyano-2-methyl-4-phenylamino-1,2,3,4-tetrahydroquinoline [Compound (14)];1-acetyl-4-[(4-isopropoxyphenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (18)];1-acetyl-2-methyl-4-[(4-morpholinophenyl)amino]-1,2,3,4-tetrahydroquinoline [Compound (19)];1-acetyl-4-[(4-N,N-dimethylaminophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (20)];1-acetyl-7-bromo-2-methyl-4-phenylamino-1,2,3,4-tetrahydroquinoline [Compound (23)];1-acetyl-4-[(4-hydroxyphenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (24)]; 1-acetyl-2-methyl-4-[(1,1′-biphenyl-4-yl)amino]-1,2,3,4-tetrahydroquinoline [Compound (25)];1-acetyl-2-methyl-4-phenoxy-1,2,3,4-tetrahydroquinoline [Compound (26)];1-acetyl-4-(4-fluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (27)];1-acetyl-4-(3-fluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (28)];1-acetyl-4-(2-fluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (29)];1-acetyl-4-(2,4-difluorophenoxy)-2-methyl-1,2,3,4-tetrahydroquinoline [Compound (30)];1-acetyl-4-(3,4-difluorophenoxy)- ...

Подробнее
04-07-2013 дата публикации

3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS

Номер: US20130172353A1
Принадлежит: ALLERGAN, INC.

This invention is directed to a compound of Formula I 2. The compound of claim 1 , wherein Xis N and Xis S.3. The compound of claim 1 , wherein Xis S and Xis N.4. The compound of claim 1 , wherein L′ is selected from the group consisting of —N(H)— claim 1 , —N(H)—C(═O)— claim 1 , —N(H)—C(═O)—N(H)— claim 1 , —O—C(═O)—N(H)— claim 1 , —N(R)—C(═O)— claim 1 , and —C(═O)—N(R)—.5. The compound of claim 1 , wherein Lis selected from the group consisting of a covalent bond claim 1 , —N(H)— claim 1 , —N(H)—C(═O)— claim 1 , —C(═O)—N(R)— claim 1 , and —N(H)—C(═O)—N(H)—.6. The compound of claim 1 , wherein n is 0 or 1.8. The compound of claim 1 , wherein Ris selected from the group consisting of H claim 1 , —NO claim 1 , hydroxy claim 1 , and aryl that is unsubstituted or substituted with one to two substituents selected from the group consisting of methyl claim 1 , fluoro claim 1 , and trifluoromethyl.12. The compound of claim 10 , wherein:{'sup': '1', 'Lis selected from the group consisting of —N(H)—, —N(H)—C(═O)—N(H)— and —O—C(═O)—N(H)—;'}{'sup': '2', 'Lis selected from the group consisting of a covalent bond, —N(H)—, —N(H)—C(═O)— and —N(H)—C(═O)—N(H)—;'}{'sup': '1', 'Ris methyl;'}{'sup': '2', 'sub': 2', '3', '2', '2', '3', '2', '3, 'Ris selected from the group consisting of H, morpholinyl-(CH)—, HO—C(═O)—(CH)—, CHO—(CH)—, and ethyl; and'}{'sup': '3', 'sub': '2', 'Ris selected from the group consisting of H, —NO, and aryl that is unsubstituted or substituted with one to two substituents selected from the group consisting of methyl, fluoro, and trifluoromethyl.'}14. The compound of claim 10 , selected from the group consisting of:5-{4-[3-(2-Fluoro-5-methyl-phenyl)-ureido]-phenyl}-3-[3-(3-morpholin-4-yl-propyl)-ureido]-isothiazole-4-carboxylic acid amide;5-{4-[3-(2-Fluoro-5-methyl-phenyl)-ureido]-2-methyl-phenyl}-3-[3-(3-morpholin-4-yl-propyl)-ureido]-isothiazole-4-carboxylic acid amide;3-[3-(4-Carbamoyl-5-{4-[3-(2-fluoro-5-methyl-phenyl)-ureido]-phenyl}-isothiazol-3-yl)-ureido ...

Подробнее
04-07-2013 дата публикации

PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE

Номер: US20130172571A1
Принадлежит: NATCO PHARMA LIMITED

Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid (Febuxostat, I(A)) is approved under the trademark Uloric® by the US Food and Drug Administration for the treatment of hyperuricemia and gouty arthritis. 2. Process as claimed in wherein the step(a) comprises:i. Charging 98% formic acid and 3-bromo-4-hydroxy benzaldehyde and stirring for 15 minutesii. Charging hydroxylamine hydrochloride and sodium acetateiii. Heating reaction mass to 105° to 110° C. and maintaining for five hoursiv. Cooling reaction mass to room temperature and adding water and stirring for 2 hoursv. Filtering followed by drying and taking (XVII) to next stage3. Process as claimed in wherein the step(b) comprises:i. Charging Isopropyl alcoholic hydrogen chloride to the compound (XVII) and stirring for 15 minutesii. Charging thioacetamide and heating to 50-55° C.iii. Maintaining reaction mass at the same temperature for two hoursiv. Bringing reaction mass to room temperaturev. Charging water to the reaction mass and coolingvi. Filtering, washing with water and drying and taking compound (XVIII) to next stage4. Process as claimed in wherein the step(c) comprises:I. Charging Isopropyl alcohol to the compound of formula (XVIII) and stirring for 5 minutesII. Charging Ethyl-2-chloroacto acetate and heating to reflux temperatureIII. Maintaining five hours at reflux temperatureIV. Bringing reaction mass to room temperatureV. Filtering and drying to yield compound (XIX)5. Process as claimed in wherein the step(d) comprises:I. Charging compound (XIX) and DMFII. Charging potassium carbonate and Isobutyl bromideIII. Heating reaction mass to 80-85° C. and maintaining for six hoursIV. Bringing reaction mass to room temperature and quenching into waterV. Filtering and washing with waterVI. Suspending wet salt in a ...

Подробнее
04-07-2013 дата публикации

Process for Manufacture of N-acylbiphenyl alanine

Номер: US20130172572A1
Принадлежит:

A novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors. 2. The process according to claim 1 , wherein the alkaline conditions comprise the use of a base selected from triethylamine claim 1 , pyridine claim 1 , N-methylpyrrole claim 1 , N-methylmorpholine claim 1 , sodium bicarbonate claim 1 , sodium carbonate claim 1 , potassium bicarbonate claim 1 , potassium carbonate claim 1 , sodium acetate claim 1 , potassium acetate claim 1 , sodium propionate and potassium propionate.3. The process according to ems claim 1 , wherein the reaction is carried out at a temperature of from of from 80 deg C. to reflux.5. The process according to claim 4 , wherein the reaction is carried out at a temperature of from of from room temperature to reflux.7. The process according to claim 6 , wherein the hydrogenation conditions comprise the use of hydrogen and palladium claim 6 , preferably claim 6 , palladium on charcoal.8. A process for preparing a compound of formula (3) claim 6 , as defined in claim 6 ,comprising the steps of{'claim-ref': [{'@idref': 'CLM-00001', 'claim 1'}, {'@idref': 'CLM-00001', 'claim 1'}], 'i) preparing the compound of formula (1-a), as defined in , according to the process defined in ;'}{'claim-ref': [{'@idref': 'CLM-00004', 'claim 4'}, {'@idref': 'CLM-00004', 'claim 4'}], 'ii) preparing the compound of formula (2-a), as defined in , according to the process defined in ; and'}{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, 'iii) obtaining the compound of formula (3), according to the process defined in .'}9. A process for preparing a compound of formula (3) claim 6 , as defined in claim 6 ,comprising the steps of{'claim-ref': [{'@idref': 'CLM-00004', 'claim 4'}, {'@idref': 'CLM-00004', 'claim 4'}], 'ii) preparing the compound of formula (2-a), as defined in , according to the process defined in ; and'}{'claim-ref': {'@idref': 'CLM-00006', ...

Подробнее
18-07-2013 дата публикации

COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY

Номер: US20130184236A1
Принадлежит: ONO PHARMACEUTICAL CO., LTD.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder. 2. The compound of claim 1 , wherein the compound is(1) 2-[(2-{(1R,5R)-2-oxo-5-[(1E)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid,(2) 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4S)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid, or(3) 2-[(2-{(1R,5R)-2-oxo-5-[(1E,4R)-7,8,8-trifluoro-4-hydroxy-4-methyl-1,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1,3-thiazole-4-carboxylic acid.3. The mixture in an arbitrary ratio of claim 1 , wherein the compound is 2-[(2-{(1R claim 1 ,5R)-2-oxo-5-[(1E claim 1 ,4S)-7 claim 1 ,8 claim 1 ,8-trifluoro-4-hydroxy-4-methyl-1 claim 1 ,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1 claim 1 ,3-thiazole-4-carboxylic acid and the diastereomer is 2-[(2-{(1S claim 1 ,5R)-2-oxo-5-[(1E claim 1 ,4S)-7 claim 1 ,8 claim 1 ,8-trifluoro-4-hydroxy-4-methyl-1 claim 1 ,7-octadien-1-yl]cyclopentyl}ethyl)thio]-1 claim 1 ,3-thiazole-4-carboxylic acid.5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is an agent for contracting the bladder detrusor and ...

Подробнее
18-07-2013 дата публикации

Aminooxazole Inhibitors of Cyclin Dependent Kinases

Номер: US20130184288A1
Принадлежит: NEOSOME LIFE SCIENCES, LLC

Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, CNS cancer, melanoma, ovarian cancer, and renal cancer. 110-. (canceled)13. The compound of claim 11 , wherein A is —O— or —S—.16. A method of therapeutically treating cancer claim 11 , comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 11 , wherein the cancer is mediated by an abnormal increase in activity of CDK2 claim 11 , CDK4 claim 11 , or VEGFR2.17. A method of inhibiting CDK2 claim 11 , CDK4 claim 11 , or VEGFR2 in a cell claim 11 , comprising contacting the cell with an effective amount of a compound of .18. A method of treating a disease claim 11 , comprising administering to a mammal having said disease a therapeutically effective amount of a compound of claim 11 , wherein the disease is characterized by cellular proliferation; the disease is mediated by an abnormal increase in activity of CDK2 claim 11 , CDK4 claim 11 , or VEGFR2; and the disease is associated with neo-vascularization or vascular permeability.19. The method of claim 18 , wherein the disease is selected from the group consisting of: blood vessel proliferative disorders claim 18 , including arthritis and restenosis; fibrotic disorders claim 18 , including hepatic cirrhosis and atherosclerosis; mesangial cell proliferative disorders claim 18 , including glomerulonephritis claim 18 , diabetic nephropathy claim 18 , malignant nephrosclerosis claim 18 , thrombotic microangiopathy syndromes claim 18 , proliferative retinopathies claim 18 , organ transplant rejection claim 18 , and glomerulopathies; and metabolic disorders claim 18 , including psoriasis claim 18 , diabetes mellitus claim 18 , chronic wound healing claim 18 , inflammation claim 18 , and neurodegenerative diseases.20. A method of therapeutically treating cancer ...

Подробнее
18-07-2013 дата публикации

SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME

Номер: US20130184317A1
Принадлежит:

Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. 181-. (canceled)83. The compound of wherein{'sup': 2', '6', '6a', '6b, 'sub': 6', '20', '2, 'Ris a C-Calkyl, optionally substituted with one or more substituents independently selected from halogen, —OH, —NH, —NHC(O)R, and —NRR;'}{'sup': 6', '7', '7', '7', '7, 'sub': 3', '2', '3', '2', '2', '3', '6', '5', '6', '4', '2', '6', '5', '2', '6', '4', '1', '20', '1', '20', '2', '3', '2', '3', '2', '2', '3', '1', '6', '6', '5', '6', '4', '2', '6', '5', '2', '6', '4, 'Ris —CH, —CHCH, —CHCHCH, —CH, —CHR, —CHCH, —CHCHR, aryl, heteroaryl, or —C-Calkyl, wherein each of the aryl, heteroaryl, or —C-Calkyl may optionally be substituted with one or more substituents independently selected from —NH, —OH, —CH, —CHCH—CHCHCH—C-Calkyl, —CH, —CHR, —CHCH, —CHCHRand halogen;'}{'sup': '6a', 'Rmay be H or methyl;'}{'sup': '6b', 'sub': 6', '5, 'Rmay be methyl 7-nitrobenzene[c][1,2,5]oxadiazole-4-yl, or —C(O)CH; and'}{'sup': '7', 'sub': 3', '3', '3', '2', '3', '2', '2', '2', '2', '3', '2', '3', '2, 'Rmay be —H, —CH, heteroaryl, —C(CH), —OH, —NH, —NHC(O)CH, —S(O)OH, —P(O))H, —As(O)OH, —NO, —OCH, —OCHCH, —C(O)OH, —C(O)NH, or halogen.'}84. The compound of or pharmaceutically acceptable salt thereof claim 82 , wherein Ris a C-Calkyl.85. The compound of or pharmaceutically acceptable salt thereof claim 82 , wherein Ris a straight C-Calkyl.86. The compound of or pharmaceutically acceptable salt thereof claim 82 , wherein Ris a C-Calkyl.87. The compound of or pharmaceutically acceptable salt thereof claim 82 , wherein Ris a C-Calkyl.88. The compound of or pharmaceutically acceptable salt thereof claim 82 , wherein Ris a C-Calkyl.89. The compound of or pharmaceutically acceptable salt thereof claim 82 , wherein Ris —(CH)CH.92. The pharmaceutical composition of claim 91 , wherein:{'sup': 2', '6', '6a', '6b, 'sub': 6', '20', '2, 'Ris a C-Calkyl, optionally ...

Подробнее
18-07-2013 дата публикации

Imine Compounds

Номер: US20130184320A1
Принадлежит: BASF SE

The present invention relates to imine compounds which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds. 138-. (canceled)40. The compound according to claim 39 , wherein Bis CH.41. The compound according to claim 39 , wherein Ais CH.42. The compound according to claim 39 , wherein X is selected from the group consisting of C-C-alkyl claim 39 , C-C-haloalkyl claim 39 , C-C-alkoxy-C-C-alkyl claim 39 , C-C-haloalkoxy-C-C-alkyl claim 39 , C-C-cycloalkyl and C-C-halocycloalkyl.43. The compound according to claim 39 , wherein X is selected from the group consisting of CF claim 39 , CHFand CFCl.44. The compound according to claim 39 , wherein Ris selected from the group consisting of hydrogen; cyano; C-C-alkyl which may be partially or fully halogenated and/or may be substituted by one or more radicals R; C-C-alkoxy; C-C-haloalkoxy; C-C-cycloalkyl which may be partially or fully halogenated and/or may be substituted by one or more radicals R; C-C-alkenyl which may be partially or fully halogenated and/or may be substituted by one or more radicals R; C-C-alkynyl which may be partially or fully halogenated and/or may be substituted by one or more radicals R; —C(═O)R; —C(═O)OR; —C(═O)N(R)R; —C(═S)R; —C(═S)OR; —C(═S)N(R)R; phenyl which may be substituted by 1 claim 39 , 2 claim 39 , 3 claim 39 , 4 or 5 radicals R; and a 3- claim 39 , 4- claim 39 , 5- claim 39 , 6- or 7-membered saturated claim 39 , partially unsaturated or aromatic heterocyclic ring containing 1 claim 39 , 2 or 3 heteroatoms or heteroatom groups selected from the group consisting of N claim 39 , O claim 39 , S claim 39 , NO claim 39 , SO and SO claim 39 , as ring members claim 39 , where the heterocyclic ring may be substituted by one or more ...

Подробнее
18-07-2013 дата публикации

PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF FEBUXOSTAT

Номер: US20130184466A1
Принадлежит: INTERQUIM, S.A.

The present invention relates to a novel process for preparing the crystalline form II of febuxostat by crystallization of a solvent selected from ethyl acetate, methyl acetate or ethyl formiate. 1. A process for preparing the crystalline form II of febuxostat , comprising the following steps:a) Dissolving febuxostat in a solvent selected from the group consisting of ethyl acetate, methyl acetate and ethyl formiate in a proportion from 10 to 60 ml of solvent per gram of solute, at a temperature between 50° C. and boiling temperature of the solution;b) Forming the crystals by cooling the solution from step a) at a temperature between 20° C. and 45° C., optionally over a period of 0.5-2 hours under stirring;c) Cooling the suspension from step b) at a temperature between 0° C. and 30° C. over a period of 0.5-3 hours; andd) Isolating the crystalline form II of febuxostat by filtration and drying.2. The process according to claim 1 , step a) claim 1 , wherein the proportion of solvent per gram of solute is from 15 to 50 ml.3. The process according to claim 1 , step b) claim 1 , wherein the temperature ranges from 33° C. to 37° C.4. The process according to claim 1 , step b) claim 1 , wherein the period is 1 hour.5. The process according to claim 1 , which comprises -between step b) and step c)-increasing yield of step b) by eliminating 40-80% of the solvent by distillation under reduced pressure at a temperature between 30° and 40° C.6. The process according to claim 5 , wherein the temperature ranges from 33° C. to 37° C. The present invention relates to a process for preparing the crystalline form II of febuxostat (2-[3-cyano-4-(2-i-butoxy)phenyl]-4-methyl-5-thiazole-carboxylic acid). Febuxostat is an inhibitor of xanthine oxidase that is indicated in the treatment of hyperuricemia. Its structural formula is as follows:CN101139325A relates to two crystalline forms of febuxostat by using ethanol, ethyl acetate or acetone. Among them form II is described, but operational ...

Подробнее
18-07-2013 дата публикации

PROCESS AND COMPOSITION OF MAKING POLYMERIZABLE RESINS CONTAINING OXAZOLIDONE

Номер: US20130184467A1
Автор: JIN XIAOMING
Принадлежит: DENTSPLY INTERNATIONAL INC.

Disclosed herein are a process and composition to make polymerizable resins containing oxazolidone, in which organic acid-catalyzed and/or thermal annealing process got involved and consequently promoted a unique intramolecular transformation from a linear urethane linkage to a cyclic urethane linkage for those specifically constructed urethane resins containing α-substituted β-ketone moieties. 1. A process , comprising:reacting at least two isocyanates and an α-substituted β-ketone to form a linear condensate,converting the linear condensate into a cyclic oxazolidone based resin or polymer,wherein converting the linear condensate is induced by thermally annealing the linear condensate at a temperature of from about 25° C. to about 150° C., or by reacting the linear condensate in the presence of an acid at a temperature of from about 23° C. to about 27° C.4. The process according to claim 1 , wherein the linear condensate includes a linear urethane linkage.5. The process according to claim 1 , wherein the linear condensate includes polymerizable groups that remain intact even after the linear condensate is converted into the cyclic oxazolidone based resin or polymer.6. The process according to claim 5 , wherein the polymerizable groups are acrylate claim 5 , methacrylate claim 5 , vinyl or combinations thereof.7. The process according to claim 1 , wherein the amount of acid present during converting the linear condensate into the cyclic oxazolidone based resin or polymer is from about 0.1 weight percent to about 5 weight percent of the resin or polymer.8. The process according to claim 1 , wherein the acid is an organic acid or an inorganic acid.9. The process according to claim 8 , wherein the organic acid is a carboxylic acid claim 8 , a sulfonic acids claim 8 , a compound having a thiol group claim 8 , a compound having an enol group claim 8 , or methacrylic acid.10. The process according to claim 9 , wherein the organic acid is formic acid claim 9 , acetic acid ...

Подробнее
18-07-2013 дата публикации

PROCESS FOR THE PREPARATION OF PROPIONIC ACID DERIVATIVES

Номер: US20130184468A1
Принадлежит: Hoffmann-La Roche Inc.

The invention relates to a process for the preparation of a compound of formula (I) 2. A process according to claim 1 , wherein Ris selected from the group consisting of:hydrogen, iso-propyl, phenyl and benzyl.3. A process according to claim 1 , wherein Ris selected from the group consisting of:phenyl, 3,5-di-methylphenyl and 3,5-di-tert-butyl-phenyl.4. A process according to claim 1 , wherein the compound of formula (III) is selected from the group consisting of:{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-benzyloxazol-2-yl]-7′-diphenylphosphino-1,1′-spirobiindane;'}{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-benzyloxazol-2-yl]-7′-di(3,5-di-methylphenyl)phosphino-1,1′-spirobiindane;'}{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-benzyloxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane;'}{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-phenyloxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane;'}{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-isopropyloxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane; and'}{'sub': 'a', '(S)-7-[4,5-Dihydrooxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane.'}5. A process according to claim 1 , wherein the compound of formula (III) is selected from the group consisting of:{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-benzyloxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane;'}{'sub': 'a', '(S,S)-7-[4,5-Dihydro-4-isopropyloxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane; and'}{'sub': 'a', '(S)-7-[4,5-Dihydrooxazol-2-yl]-7′-di(3,5-di-tert-butylphenyl)phosphino-1,1′-spirobiindane.'}6. A process according to claim 1 , wherein the catalyst is Ir(L)(L)Ywherein:Ir is iridium;{'sup': '1', 'Lis a compound of formula (III);'}{'sup': '2', 'Lis selected from the group consisting of: cyclooctene, 1,5-cyclooctadiene, ethylene, 1,5-hexadiene and norbornadiene;'}Y is selected from the group consisting of: chloride, iodide, bromide, fluoride, trifluoroacetate, tetrafluoroborate, ...

Подробнее
25-07-2013 дата публикации

SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF

Номер: US20130190366A1
Принадлежит: CADILA HEALTHCARE LIMITED

Substantially pure salts of febuxostat of Formula (IA): wherein Y is Na, K, Li, Mg, Ca, Zn, Ba, Sr, choline, epolamine and N(R)and processes for preparation thereof are disclosed. 3. Febuxostat sodium having purity greater than 99.5% by area percentage of HPLC.5. Febuxostat potassium having purity greater than 99.5% by area percentage of HPLC.7. The process as claimed in claim 6 , wherein the base comprises one or more of sodium hydroxide claim 6 , potassium hydroxide claim 6 , lithium hydroxide claim 6 , calcium hydroxide claim 6 , barium hydroxide claim 6 , strontium hydroxide claim 6 , zinc hydroxide claim 6 , choline hydroxide claim 6 , epolamine hydroxide claim 6 , sodium carbonate claim 6 , potassium carbonate claim 6 , lithium carbonate claim 6 , magnesium carbonate claim 6 , calcium carbonate claim 6 , sodium bicarbonate claim 6 , potassium bicarbonate claim 6 , lithium bicarbonate claim 6 , sodium methoxide claim 6 , potassium t-butoxide claim 6 , magnesium methoxide claim 6 , and the like.8. The process as claimed in claim 6 , wherein the organic solvent comprises one or more of aliphatic alcohols claim 6 , aliphatic ketones claim 6 , polar aprotic solvents claim 6 , or mixtures thereof.9. The process as claimed in claim 8 , wherein the alcohol comprises one or more of methanol claim 8 , ethanol claim 8 , n-propanol claim 8 , isopropanol claim 8 , n-butanol claim 8 , and tert-amyl alcohol.10. The process as claimed in claim 8 , wherein the aliphatic ketones comprises one or more of acetone claim 8 , methylethylketone claim 8 , and methylisobutyl ketone.11. The process as claimed in claim 8 , wherein the polar aprotic solvent comprises one or more of dimethylformamide claim 8 , dimethylacetamide claim 8 , dimethylsulfoxide claim 8 , and N-methylpyrrolidone.12. The process as claimed in claim 6 , wherein the isolation comprises one or more of filtration claim 6 , filtration under vacuum claim 6 , evaporation claim 6 , decantation claim 6 , centrifugation ...

Подробнее
01-08-2013 дата публикации

3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES

Номер: US20130196984A1
Принадлежит:

The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I 2. The compound of claim 1 , whereinX is O or S,{'sup': '1', 'claim-text': i) lower alky, and', 'ii) cycloalkyl,, 'Ris selected from the group consisting of'}{'sup': '2', 'claim-text': i) aryl substituted by 1-4 substituents individually selected from cyano, halogen and heteroaryl,', 'ii) cycloalkyl,', 'iii) cycloalkyl substituted by 1-4 substituents individually selected from halogen, halogen-lower alkyl, lower alkoxy-lower alkyl and lower alkyl,', 'iv) heteroaryl,', 'v) heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, halogen, halogen-lower alkoxy, halogen-lower alkyl, cycloalkyl-lower alkoxy, lower alkenyl-lower alkoxy, aryl-lower alkoxy, heteroaryl, heterocyclyl, and lower alkyl, and', 'vi) heterocyclyl,, 'Ris selected from the group consisting of'}{'sup': '3', 'Ris halogen,'}{'sup': '4', 'Ris H or lower alkyl,'}{'sup': '5', 'Ris H or lower alkyl,'}{'sup': '6', 'Ris H or lower alkyl,'}{'sup': '7', 'Ris H, aryl or lower alkyl, and'}n is 0 or 1or a pharmaceutically acceptable salt thereof.4. The compound of claim 1 , wherein X is O.5. The compound of claim 1 , wherein Ris lower alkyl or cycloalkyl.6. The compound of claim 5 , wherein Ris methyl or cyclopropyl.7. The compound of claim 1 , wherein Ris selected from the group consisting ofi) aryl substituted by 1-4 substituents individually selected from cyano, halogen and heteroaryl,ii) cycloalkyl,iii) cycloalkyl substituted by 1-4 substituents individually selected from halogen, halogen-lower alkyl and lower alkoxy-lower alkyl,iv) heteroaryl,v) heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, halogen, halogen-lower alkoxy, halogen-lower alkyl, cycloalkyl-lower alkoxy, lower alkenyl-lower alkoxy, aryl-lower alkoxy, heteroaryl, heterocyclyl, and lower alkyl, andvi) heterocyclyl.8. The compound of claim 1 , wherein Ris aryl substituted by 1-4 halogens claim 1 , ...

Подробнее
08-08-2013 дата публикации

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

Номер: US20130203729A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula (I): 7. The compound of claim 1 , whereinn is 1;{'sup': 2', '3', '2', '3, 'sub': 3', '3, 'Rand Rare independently selected from H, —CH, —Cl, —F, —CN and —CF, provided that at least one of Ror Ris H;'}{'sup': 5', '4, 'sub': 3', '2', '3', '3, 'Ris selected from —CH, —CHCH, —OCFand —CN and is bonded to a position on the phenyl ring meta to R;'}{'sup': 8', '8, 'sub': 3', '3', '2', '3', '3', '2, 'Ris selected from azepan-1-yl, azetidin-1-yl, morpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl, [1,4]oxazepan-4-yl, and piperidin-1-yl, wherein each Ris optionally substituted with one to three groups independently selected from —CH, —OCH, —CHOH, —OCH, —N(CH), —OH, oxo, —CN and halogen;'}{'sup': '9', 'sub': 3', '2', '3', '3, 'Ris a heterocyclyl selected from morpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl and piperazin-1-yl, wherein said heterocyclyl is optionally substituted with one to three groups independently selected from —CH, —CHCH, Cl, F, oxo, —OH, —C(O)CH, —C(O)cyclopropyl and —C(O)tetrahydrofuran-3-yl;'}or a salt thereof.8. The compound of claim 1 , wherein{'sup': 4', '8, 'Ris —C(O)R;'}or a salt thereof.9. The compound of claim 1 , wherein{'sup': 4', '9, 'sub': '2', 'Ris —CHR;'}or a salt thereof.11. The compound of selected from the group consisting of compound numbers 1 claim 10 , 13 claim 10 , 15 claim 10 , 17 claim 10 , 20 claim 10 , 21 claim 10 , 28 claim 10 , 30 claim 10 , 36 claim 10 , 39 claim 10 , 41-43 claim 10 , 49 claim 10 , 52 claim 10 , 59 claim 10 , 62 claim 10 , 63 claim 10 , 65 claim 10 , 67-70 claim 10 , 72-74 claim 10 , 79 claim 10 , 81 claim 10 , 84 claim 10 , 88-90 claim 10 , 92 claim 10 , 95 claim 10 , 97 claim 10 , 102-108 claim 10 , 111 claim 10 , 113 claim 10 , 117-120 claim 10 , 122-126 claim 10 , 129-133 claim 10 , 136-138 claim 10 , 140-144 claim 10 , 151-153 claim 10 , 161 claim 10 , 162 claim 10 , 164 claim 10 , 167 claim 10 , 173 ...

Подробнее
15-08-2013 дата публикации

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY

Номер: US20130210769A1
Принадлежит: IRM LLC

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1). 2. The compound of in which Ris selected from cyano claim 1 , methyl-carbonyl-amino-sulfonyl-ethyl claim 1 , pyrrolidin-2-onyl-ethyl claim 1 , imidazolyl-ethyl claim 1 , oxazolidin-2-only-ethyl claim 1 , 1-pyrazolyl-ethyl claim 1 , cyano-methyl claim 1 , 4′-(4-chlorophenoxy)phenyl claim 1 , 1 claim 1 ,3-dioxanyl-ethyl claim 1 , allyl claim 1 , phenyl claim 1 , pyrazinyl claim 1 , piperazinyl-sulfonyl-ethyl claim 1 , azetidinyl-sulfonyl-ethyl claim 1 , morpholino-sulfonyl-ethyl claim 1 , pyrrolidinyl-sulfonyl-ethyl claim 1 , pyrrolidinyl-propyl claim 1 , pyrrolidinyl-ethyl claim 1 , piperazinyl-propyl claim 1 , piperidinyl-sulfonyl-ethyl claim 1 , pyridazinyl claim 1 , (5-(4-methoxyphenyl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)methyl claim 1 , isoxazolyl claim 1 , piperidinyl-carbonyl-methyl claim 1 , 3-(N claim 1 ,N-bis(4-methoxyphenyl)sulfamoyl)propyl claim 1 , methyl-phenyl-sulfonyl claim 1 , cyanomethyl claim 1 , 2-oxo-2-(piperidin-1-ylamino)ethyl claim 1 , propyl-amino-carbonyl-methyl claim 1 , 2-(carboxymethylamino)-2-oxoethyl) claim 1 , bis-hydroxyethyl-amino-sulfonyl-ethyl claim 1 , carboxy-methyl-amino-carbonyl-methyl claim 1 , amino-carbonyl-ethyl claim 1 , amino-sulfonyl-ethyl claim 1 , amino-sulfonyl-propyl claim 1 , methyl-amino-ethyl claim 1 , piperidinyl-ethyl claim 1 , piperazinyl-ethyl claim 1 , methyl-sulfonyl-ethyl claim 1 , carboxy-methyl claim 1 , tetrazole-methyl claim 1 , benzyl claim 1 , 1 claim 1 ,2 claim 1 ,4-oxadiazole claim 1 , 1 claim 1 ,2 claim 1 ,4-oxadiazole-methyl claim 1 , 1 claim 1 ,2 claim 1 ,4-oxadiazole-ethyl claim 1 , isoxazole-methyl claim 1 , 2-(2-hydroxyethylamino)-2-oxoethyl claim 1 , dimethylamino-ethyl-amino-carbonyl-methyl claim 1 , hydroxyl-ethyl claim 1 , methoxy-ethyl claim 1 , hydroxyl-ethyl- ...

Подробнее
15-08-2013 дата публикации

ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

Номер: US20130210797A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension. 4. The method of claim 1 , wherein the compound of formula (I) is selected from:2-{4-[2-Amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-lysyl-D-alaninate-Dihydrochloride,2-{4-[2-Amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-arginyl-D-alaninate-Dihydrochloride,2-{4-[2-Amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-lysyl-D-valinate-Dihydrochloride,2-{4-[2-Amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-arginyl-D-valinate-Trihydrochloride,2-{4-[2-Amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-lysyl-D-phenylalaninate-Dihydrochloride,2-{4-[2-(Azetidin-1-yl)-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-beta-alaninate-Trifluoroacetate,2-{4-[2-(Azetidin-1-yl)-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-ornithinate-Bis(trifluoroacetate),2-{4-[2-(Azetidin-1-yl)-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl-L-lysyl-L-alaninate-Bis(trifluoroacetate),2-{4-[2-({[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-L-alanyl-L-alaninate-Hydrochloride,2-{4-[2-({[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-L-isoleucyl-L-alaninate-Hydrochloride,2-{4-[2-({[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]methyl} ...

Подробнее
15-08-2013 дата публикации

7-AZA-SPIRO[3,5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

Номер: US20130211087A1
Принадлежит: SANOFI

The present invention is directed to 7-aza-spiro[3.5]nonane-7-carboxylate derivatives of the Formula I. The compounds of the invention are inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The invention also relates to processes for the preparation of compounds of the Formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them. 111-. (canceled)1720-. (canceled) This application is a divisional of U.S. application Ser. No. 13/320,199 filed Nov. 11, 2011, which is a National Stage of PCT/FR2010/850914 filed May 11, 2010, which claims the benefit of priority of French patent application Ser. No. 09/02269, filed May 12, 2009.The subject of the invention is 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, the preparation thereof and the therapeutic use thereof.There is still a need to find and develop products which inhibit the enzyme FAAH (Fatty Acid Amide Hydrolase). The compounds of the invention meet this purpose.The compounds of the invention correspond to the general formula (I):in whichRrepresents a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C-alkyl, C-alkoxy or NRRgroup;m, n, o and p independently of one another represent a number ranging from 0 to 3; it being understood that 2≦m+n≦5 and that 2≦o+p≦5;A represents a covalent bond, an oxygen atom, a C-alkylene group or an —O—C-alkylene group in which the end represented by an oxygen atom is linked to the group Rand the end represented by an alkylene group is linked to the carbon of the bicyclic system;Rrepresents a group Roptionally substituted with one or more groups Rand/or R;Rrepresents a group selected from a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthalenyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl group;Rrepresents a halogen atom, a cyano, —CHCN, nitro, hydroxyl, C-alkyl, C-alkoxy, C-thioalkyl, C-haloalkyl, C-haloalkoxy, C- ...

Подробнее
15-08-2013 дата публикации

SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS

Номер: US20130211092A1

The present invention provides novel methods for synthesizing PPARγ sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases. 4. The method of claim 3 , wherein Ris methyl claim 3 , ethyl claim 3 , propyl claim 3 , isopropyl claim 3 , butyl claim 3 , or tert-butyl claim 3 , each of which is optionally substituted.8. The method of claim 7 , wherein Xis a halo or triflyl group.11. The method of claim 10 , further comprising halogenating the compound of Formula 6A to generate the compound of Formula 5A.13. The method of claim 12 , wherein Ris a Calkyl optionally substituted with 1-3 halo.14. The method of claim 13 , wherein Ris selected from methyl claim 13 , ethyl claim 13 , or propyl claim 13 , any of which is optionally substituted with 1-3 halo.18. The method of claim 17 , wherein the compound of Formula 7A is converted to a compound of Formula 2A under reduction conditions.19. The method of claim 17 , wherein the compound of Formula 2A is generated by treating the compound of Formula 7A with a reducing reagent comprising NaBH.27. The method of claim 26 , wherein Ris methyl claim 26 , ethyl claim 26 , propyl claim 26 , isopropyl claim 26 , butyl claim 26 , or tert-butyl claim 26 , each of which is optionally substituted.31. The method of claim 30 , wherein Xis a halo or triflyl group.34. The method of claim 33 , further comprising halogenating the compound of Formula 6A to generate the compound of Formula 5A.36. The method of claim 35 , wherein Ris a Calkyl optionally substituted with 1-3 halo.37. The method of claim 36 , wherein Ris selected from methyl claim 36 , ethyl claim 36 , or propyl claim 36 , any of which is optionally substituted with 1-3 halo.40. The compound of claim 39 , wherein Ris an unsubstituted Calkyl.41. The compound of claim 40 , wherein Ris methyl claim 40 , ethyl claim 40 , propyl claim 40 , isopropyl claim 40 , butyl ...

Подробнее
22-08-2013 дата публикации

SYNTHESIS OF ENONE INTERMEDIATE

Номер: US20130217886A1

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate. 1102-. (canceled)104. The method of claim 103 , wherein Ris hydrogen.105. The method of claim 103 , wherein Rand Rare hydrogen.106. The method of claim 103 , wherein Ris —N(R).107. The method of claim 106 , wherein Ris —N(CH).108. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris halogen.109. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris —NHC(O)R.110. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris —OR.111. The method of claim 103 , wherein n is not 0 claim 103 , and at least one instance of Ris cyclic or acyclic claim 103 , substituted or unsubstituted claim 103 , branched or unbranched heteroaliphatic.112. The method of claim 103 , wherein deprotecting the enolate of the ketone (VII) under suitable conditions comprises use of BBror BCl.114. The method of claim 113 , wherein the lipase is Amano Lipase AK.115. The method of claim 113 , wherein the suitable conditions comprise the presence of vinyl acetate.117. The method of claim 116 , wherein the vinyl reagent is a metal vinyl reagent. The present application is a continuation of and claims priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 13/043,742, filed Mar. 9, 2011, which is a continuation of and claims priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 12/833,628, filed Jul. ...

Подробнее
29-08-2013 дата публикации

QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO

Номер: US20130225612A1
Принадлежит: EMORY UNIVERSITY

The invention relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the invention relates to inhibitors of NADPH-oxidase. 3. The composition of claim 2 , wherein Ris halogen Ris hydrogen claim 2 , Ris halogen Ris halogen claim 2 , Ris alkoxy and Ris alkoxy claim 2 , or Rand Rform a ring from —OCHO— or —OCHCHO—.4. The composition of claim 2 , wherein Ris phenyl.8. The composition of claim 7 , wherein Ris halogen.9. The composition of claim 1 , wherein the compound is selected from:3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(2-(diethylamino)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(4-(dimethylamino)butyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(1-methylpiperidin-4-yl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(2-(dimethylamino)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(5-(dimethylamino)pentyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one hydrochloride,3-(2-(pyrrolidin-1-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one hydrochloride,3-(2-(piperidin-1-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one hydrochloride,3-(3-morpholinopropyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(3-(4-methylpiperazin-1-yl)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one hydrochloride,3-(2-(dipropylamino)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,6-chloro-3-(2-(diethylamino)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,7-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(3-(dimethylamino)propyl)-6,7-dimethoxy-2-thioxo-2,3-dihydroquinazolin-4(1H)-one hydrochloride,3-(3-(dimethylamino)propyl)-6,7-difluoro-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,6,8-dichloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,6-chloro-3-(2-(piperidin-1-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,3-(3-(dimethylamino)propyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1H)-one,1- ...

Подробнее
29-08-2013 дата публикации

Method for preparing substituted isoxazoline compounds and their precursors 4-chloro, 4-bromo- or 4-iodobenzaldehyde oximes

Номер: US20130225826A1
Принадлежит: BASF SE

The present invention relates to a method for preparing 4-chloro-, 4-bromo- or 4-iodobenzaldehyde oximes and phenyl-substituted isoxazoline compounds prepared from these oximes. 129-. (canceled)32. The method as claimed in claim 30 , where step (ii) is carried out at a pH of at least 5.1.33. The method as claimed in claim 32 , where step (ii) is carried out at a pH of 5.1 to 14.34. The method as claimed in claim 30 , where step (ii) is carried out in the presence of a Cu(I) salt.35. The method as claimed in claim 34 , where the Cu(I) salt is generated in situ by carrying out step (ii) in the presence of a Cu(II) salt and a reduction agent.36. The method as claimed in claim 35 , where the reduction agent is selected from the group consisting of sulfite salts claim 35 , dithionite salts claim 35 , thiosulfate salts claim 35 , meta-bisulfite salts claim 35 , hydroxymethanesulfinate salts claim 35 , SnCl claim 35 , Zn and hydrazine.37. The method as claimed in claim 30 , where in step (ii) the diazonium salt is added to a solution containing the formoxime claim 30 , a copper salt and claim 30 , if the copper salt is a Cu(II) salt claim 30 , also a reduction agent.38. The method as claimed in claim 37 , where the diazonium salt is cooled to -10 to +15° C. before being added to the solution containing the formoxime claim 37 , a copper salt and claim 37 , if the copper salt is a Cu(II) salt claim 37 , also a reduction agent.39. The method as claimed in claim 37 , where the solution containing the formoxime claim 37 , a copper salt and claim 37 , if the copper salt is a Cu(II) salt claim 37 , also a reduction agent claim 37 , is adjusted to a pH of >5 claim 37 , before the diazonium salt is added.40. The method as claimed in claim 30 , where in the course of the reaction of step (ii) the pH is controlled continuously or periodically and if necessary adjusted to a pH of >5.41. The method as claimed in claim 30 , where the adjustment of the pH is performed by using a system ...

Подробнее
29-08-2013 дата публикации

FLUORINATION PROCESS

Номер: US20130225829A1
Принадлежит:

The invention relates to a process for preparation of a compound of formula (I): 1. (canceled)2. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. A compound of formula (IIa) or (IIIa) as defined in .14. A compound of formula (IIb) according to wherein Ris hydrogen claim 13 , and Ris nitro.15. A compound 2-[3-nitro-4-(methylformylamino)phenyl]-6-ethoxymethoxy-benzothiazole.17. A cartridge for a radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET which comprises:{'claim-ref': {'@idref': 'CLM-00012', 'claim 12'}, '(i) a vessel containing a compound of formula (IIa) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F.'}18. A process according to claim 4 , wherein Ris hydroxy claim 4 , Calkoxy claim 4 , or a protected derivative thereof.19. A process according to claim 4 , wherein Ris hydroxy claim 4 , methoxy claim 4 , or a protected derivative thereof.21. A cartridge for a radiopharmaceutical kit for the preparation of an F-labelled tracer for use in PET which comprises:{'claim-ref': {'@idref': 'CLM-00013', 'claim 13'}, '(i) a vessel containing a compound of formula (IIb) as defined in ; and'}{'sup': 18', '−, '(ii) means for eluting the vessel with a source of F.'} The present invention relates to novel processes for fluorination, particularly [F]fluorination of certain aromatic compounds, and to the novel precursors used in the process. The invention has particular utility for a class of benzothiazole derivatives which are known as in vivo imaging agents.Fluorination of aromatic compounds may be performed via electrophilic reaction with molecular fluorine, however, electrophilic fluorination of aromatic compounds with fluorine is generally a poor and non-selective method. Different electrophilic fluorinating reagents prepared from molecular fluorine, such as CHCOOF “AcOF” have been developed but suffer several drawbacks. For [F] ...

Подробнее
29-08-2013 дата публикации

POLYMORPHS OF FEBUXOSTAT

Номер: US20130225830A1
Автор: Marom Ehud, Rubnov Shai
Принадлежит: MAPI PHARMA LIMITED

The present invention provides new crystalline forms of febuxostat, pharmaceutical compositions comprising same, methods for their preparation and use thereof in treating hyperuricaemia. 153-. (canceled)54. A crystalline anhydrous febuxostat (Form IX) having an X-ray powder diffraction pattern with diffraction peaks at 2-theta values of about 4.6±0.1 , 6.1±0.1 , 7.3±0.1 , 9.2±0.1 , 11.6±0.1 , 13.3±0.1 , 16.3±0.1 , 17.3±0.1 , 18.5±0.1 , 23.0±0.1 , 25.7±0.1 , 26.5±0.1 and 28.3±0.1.5542. The crystalline anhydrous febuxostat (Form IX) according to having an X-ray powder diffraction pattern substantially as shown in any of or .56. The crystalline anhydrous febuxostat (Form IX) according to claim 54 , further characterized by:{'figref': {'@idref': 'DRAWINGS', 'FIG. 32'}, 'b': '43', '(a) a DSC profile substantially as shown in any of or ; or'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 33'}, 'b': '44', '(b) TGA profile substantially as shown in any of or ; or'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 34'}, '(c) an IR spectrum substantially as shown in ; or'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 35'}, '(d) an FT-Raman spectrum substantially as shown in .'}57. The crystalline anhydrous febuxostat (Form IX) according to claim 56 ,{'sup': '−1', 'wherein the IR spectrum has characteristic peaks at about 657±4, 715±4, 764±4, 825±4, 874±4, 911±4, 952±4, 1010±4, 1037±4, 1114±4, 1168±4, 1281±4, 1328±4, 1370±4, 1389±4, 1427±4, 1450±4, 1511±4, 1606±4, 1687±4, 2235±4, 2868±4 and 2962±4 cm; or'}{'sup': '−1', 'wherein the FT-Raman spectrum has characteristic peaks at about 392±4, 467±4, 585±4, 748±4, 1047±4, 1175±4, 1332±4, 1374±4, 1431±4, 1512±4, 1609±4, 1842±4, 1892±4, 1973±4, 2081±4, and 2235±4 cm.'}59. A crystalline febuxostat NMP solvate (Form IV) having an X-ray powder diffraction pattern with diffraction peaks at 2-theta values of about 4.0±0.1 claim 56 , 4.9±0.1 claim 56 , 6.4±0.1 claim 56 , 6.9±0.1 claim 56 , 7.5±0.1 claim 56 , 8.0±0.1 claim 56 , 8.3±0.1 claim 56 , 10.1±0.1 claim ...

Подробнее
05-09-2013 дата публикации

Bridged Spiro[2.4]heptane Ester Derivatives

Номер: US20130231319A1
Принадлежит: ACTELION PHARMACEUTICALS LTD.

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method. 2. The compound according to claim 1 , whereinY represents a bond or a methandiyl group;{'sup': '1', 'sub': 1', '4', '1', '4', '1', '2, 'Rrepresents an aryl- or a heteroaryl-group, wherein the groups are independently unsubstituted, mono- or di-substituted, wherein the substituents are independently halogen, (C-C)alkyl, (C-C)alkoxy or (C-C)fluoroalkyl;'}{'sup': '2', 'claim-text': [{'sup': 3', '4, 'sub': '2', 'cyclopentyl or cyclohexyl, which are independently unsubstituted or mono-substituted with RRN—CH— or heterocyclyl-methyl;'}, {'sub': 2', '6', '1', '4, 'sup': 3', '4', '5', '6, '(C-C)alkyl, which is mono-substituted with —NRR, —C(O)NRR, or (C-C)alkoxy which is mono-substituted with heterocyclyl, wherein the heterocyclyl is unsubstituted or mono- or di-substituted at one of the carbon atoms with fluoro; or'}, {'sub': 1', '6, 'claim-text': [{'sub': 1', '4, 'with heterocyclyl, wherein the heterocyclyl is unsubstituted, or mono-substituted at a nitrogen atom with (C-C)alkyl and/or mono- or di-substituted at ...

Подробнее
05-09-2013 дата публикации

PHARMACEUTICAL COMPOUNDS

Номер: US20130231340A1
Автор: Reader John Charles
Принадлежит: SAREUM LIMITED

The invention provides a method of inhibiting a TYK2 kinase, which method comprises bringing into contact with the TYK2 kinase an effective TYK2 kinase-inhibiting amount of a compound having the formula (0): 3. A method according to wherein the optional substituents for Arare independently selected from fluorine claim 2 , chlorine claim 2 , bromine claim 2 , methyl claim 2 , ethyl claim 2 , isopropyl claim 2 , hydroxymethyl claim 2 , hydroxyethyl claim 2 , methoxyethyl claim 2 , methoxy claim 2 , ethoxy claim 2 , isopropoxy claim 2 , methoxyethoxy claim 2 , cyano claim 2 , acetyl claim 2 , acetoxy claim 2 , trifluoromethyl claim 2 , trifluoromethoxy claim 2 , difluoromethyl and difluoromethoxy.4. A method according to wherein Aris selected from 2 claim 3 ,6-difluorophenyl claim 3 , 2-chloro-6-fluorophenyl and 2 claim 3 ,6-dichlorophenyl.5. A method according to wherein A is NRand Qis C(═O).6. A method according to wherein A is absent and Qis SO.7. A method according to wherein Ris selected from:hydrogen;{'sub': 1-4', '1-3, 'a Calkyl group optionally substituted with one or more substituents selected from hydroxy, amino and mono-Calkylamino; and'}{'sub': 1-3', '1-3, '5 to 6-membered heterocyclic rings selected from pyrrolidine, piperidine, piperazine and morpholine, the heterocyclic rings being optionally substituted with one or more Calkyl or hydroxy-Calkyl groups;'}{'sup': '2', 'sub': '1-2', 'R, when present, is selected from hydrogen and Calkyl; or'}{'sup': 1', '2, 'sub': 1-3', '1-3, 'NRRforms a 5 to 6-membered heterocyclic ring selected from pyrrolidine, piperidine, piperazine and morpholine, the heterocyclic ring being optionally substituted with one or more Calkyl or hydroxy-Calkyl groups.'}9. A method according to wherein the compound of formula (1) is selected from:2-(2,6-difluorophenyl)-5-(4-(methylsulfonyl)phenylamino)oxazole-4-carboxamide;2-(2,6-difluorophenyl)-5-(4-sulfamoylphenylamino)oxazole-4-carboxamide;2-(2,6-difluorophenyl)-5-(4-(N,N- ...

Подробнее
05-09-2013 дата публикации

PACTAMYCIN ANALOGS AND METHODS OF USE

Номер: US20130231377A1
Автор: Mahmud Taifo
Принадлежит:

Disclosed are pactamycin analogs, pharmaceutical compositions including the analogs, and methods of using the analogs, such as to inhibit tumor growth or a pathogenic infection such as a bacterial or parasitic infection. The pactamycin analogs have a general formula 4. The method of claim 1 , wherein Rand Rtogether form a heterocyclic 5-membered ring.56-. (canceled)7. The method of claim 1 , wherein Rand Rtogether form a heterocyclic 5-membered ring.8. (canceled)9. The method of claim 1 , wherein Ris a substituted benzoyl group.10. (canceled)1213-. (canceled)17. The compound of claim 14 , wherein Rand Rtogether form a heterocyclic 5-membered ring.18. (canceled)19. The compound of claim 14 , wherein Rand Rtogether form a heterocyclic 5-membered ring.20. (canceled)21. The compound of claim 14 , wherein Ris a substituted benzoyl group.22. (canceled)24. A pharmaceutical composition claim 14 , comprising a compound according to and a pharmaceutically acceptable carrier.25. A method of inhibiting a tumor in a subject claim 14 , comprising:selecting a subject for treatment that has, or is at risk for developing, a tumor;{'claim-ref': {'@idref': 'CLM-00024', 'claim 24'}, 'administering to the subject an effective amount of the pharmaceutical composition of , thereby treating the tumor in the subject.'}26. A method of treating an infection from a pathogen of interest in a subject claim 14 , comprising:selecting a subject for treatment that has, or is at risk for developing, an infection by a pathogen of interest;{'claim-ref': {'@idref': 'CLM-00024', 'claim 24'}, 'administering to the subject an effective amount of the pharmaceutical composition of , thereby treating the infection from the pathogen of interest in the subject.'}27. The method of claim 26 , wherein the pathogen of interest is a Gram-positive or Gram-negative bacterial pathogen.28. A method of inhibiting growth of a pathogen claim 14 , comprising contacting the pathogen with a composition of claim 14 , wherein ...

Подробнее
12-09-2013 дата публикации

THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION

Номер: US20130236394A1
Принадлежит:

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele. 2. The compound according to claim 1 , wherein at least one of the atoms of the structure is replaced with I.3. The compound according to claim 1 , wherein at least one of the atoms of the structure is replaced with I.4. The compound according to claim 1 , wherein at least one of the atoms of the structure is replaced with I.5. The compound according to claim 1 , wherein at least one of the atoms of the structure is replaced with Br.6. The compound according to claim 1 , wherein at least one of the atoms of the structure is replaced with Br.7. The compound according to claim 1 , wherein at least one of the atoms of the structure is replaced with F.8. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier.9. A method for detecting amyloid deposits in a subject claim 1 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) administering a detectable quantity of a pharmaceutical composition comprising a compound according to , and'}(b) detecting the binding of the compound to amyloid deposit in the subject.10. The method according to claim 9 , wherein the amyloid deposit is located in the brain of a subject.11. The method according to claim 9 , wherein the subject is suspected of having a disease or syndrome selected from the group consisting of Alzheimer's Disease claim 9 , familial Alzheimer's Disease claim 9 ...

Подробнее
12-09-2013 дата публикации

SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

Номер: US20130237552A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. 2. The method of claim 1 , wherein the disorder associated with chemokine receptor modulation is an ocular inflammatory disease or a skin inflammatory disease.3. The method of claim 2 , wherein the ocular inflammatory disease is selected from: uveitis claim 2 , retinal degenerative conditions claim 2 , angiogenesis claim 2 , dry eye claim 2 , Keratitis claim 2 , allergic eye disease claim 2 , conditions affecting the posterior part of the eye claim 2 , retinal degeneration claim 2 , non-exudative age related macular degeneration claim 2 , exudative age related macular degeneration claim 2 , choroidal neovascularization claim 2 , diabetic retinopathy claim 2 , acute macular neuroretinopathy claim 2 , central serous chorioretinopathy claim 2 , cystoid macular edema claim 2 , and diabetic macular edema claim 2 , retinitis claim 2 , acute multifocal placoid pigment epitheliopathy claim 2 , Behcet's disease claim 2 , birdshot retinochoroidopathy claim 2 , multifocal choroiditis claim 2 , multiple evanescent white dot syndrome claim 2 , ocular sarcoidosis claim 2 , posterior scleritis claim 2 , serpiginous choroiditis claim 2 , subretinal fibrosis and Vogt-Koyanagi-and Harada syndrome.4. The method of claim 2 , wherein the skin inflammatory disease is selected from: rosacea claim 2 , sunburn claim 2 , chronic sun damage claim 2 , discreet erythemas claim 2 , psoriasis claim 2 , atopic dermatitis claim 2 , menopause-associated hot flashes claim 2 , hot flashes resulting from orchiectomyatopic dermatitis claim 2 , photoaging claim 2 , seborrheic dermatitis claim 2 , acne claim 2 , allergic dermatitis claim 2 , irritant dermatitis claim 2 , telangiectasia of the face claim 2 , rhinophyma claim 2 , red bulbous nose claim 2 , acne-like skin eruptions claim 2 , burning or ...

Подробнее
19-09-2013 дата публикации

NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF

Номер: US20130245008A1
Автор: Pellet Alain
Принадлежит: SANOFI

The invention relates to the nitrobenzothiazole derivatives of general formula (I): and to the use thereof for treating tuberculosis. 2. The compound of formula (I) as claimed in claim 1 , characterized in that Rrepresents:{'sub': 1', '4, 'claim-text': one or more fluorine atoms;', 'a phenyl optionally substituted with one or more groups chosen, independently of one another, from an OH, methoxy, morpholine or trifluoromethoxy group and a chlorine or fluorine atom;', 'a pyridinyl, isoxazolyl, pyrazolyl, thienyl, benzoxazolyl, tetrahydroisoquinolinyl, quinolinyl and thiazolyl group optionally substituted with one or more groups chosen, independently of one another, from a methyl or ethyl group or a chlorine atom;', 'an unsubstituted pyridinyl-NH group;', 'an unsubstituted cyclohexyl group;', 'a tetrahydropyranyl group, a morpholinyl group, a pyrrolidinyl group and a thiomorpholinyl group optionally substituted with one or more groups chosen, independently of one another, from a methyl, phenyl and benzyl group;, 'a (C-C)alkyl radical substituted withor{'sub': 1', '4, 'claim-text': 'an unsubstituted phenyl;', 'a (C-C)alkyl radical disubstituted with 'an unsubstituted morpholinyl group;', 'and'}in the form of a base or of an addition salt with an acid or with a base.3. The compound of formula (I) as claimed in claim 1 , characterized in that it corresponds to the following compounds:N-[2-(4-chlorophenyl)ethyl]-7-nitro-5-(trifluoromethyl)-1,3-benzothiazole-2-carboxamide;7-nitro-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-5-(trifluoromethyl)-1,3-benzothiazole-2-carboxamide;7-nitro-N-(2-pyridin-2-ylethyl)-5-(trifluoromethyl)-1,3-benzothiazole-2-carboxamide;7-nitro-5-(trifluoromethyl)-N-(3,3,3-trifluoropropyl)-2-benzothiazolecarboxamide;7-nitro-N-(pyridin-2-ylmethyl)-5-(trifluoromethyl)-1,3-benzothiazole-2-carboxamide;N-[3-(4-morpholinyl)propyl]-7-nitro-5-(trifluoromethyl)-2-benzothiazolecarboxamide;N-[2-(4-methoxyphenyl)ethyl]-7-nitro-5-(trifluoromethyl)-1,3-benzothiazole-2- ...

Подробнее
19-09-2013 дата публикации

CRYSTALLINE FORM OF RIVAROXABAN DIHYDRATE

Номер: US20130245017A1
Принадлежит: SANDOZ AG

The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban. 1. Crystalline dihydrate of Rivaroxaban having a X-ray powder diffraction pattern comprising peaks at 2-theta angles of 7.1° , 9.8° , 10.6° , 19.7° , 24.2° , and 27.3°+/−0.2.2. Crystalline dihydrate of Rivaroxaban according to claim 1 , having an attenuated total reflectance infrared spectrum comprising absorption bands at 3335 claim 1 , 1721 claim 1 , 1627 claim 1 , 1515 claim 1 , 1244 claim 1 , 1218 claim 1 , 1023 claim 1 , 922 claim 1 , 864 and 817±2 cm.3. Crystalline Rivaroxaban dihydrate for use in a medicament.4. Crystalline Rivaroxaban dihydrate for use in a pharmaceutical composition for oral administration claim 1 , wherein the equilibrium relative humidity of said pharmaceutical composition is above 20%.5. Pharmaceutical composition comprising crystalline dihydrate of Rivaroxaban according to .6. The pharmaceutical composition of claim 1 , wherein more than 90% of the Rivaroxaban is stably present as crystalline dihydrate of Rivaroxaban according to .7. A container comprising a pharmaceutical composition according to and a means to keep the equilibrium relative humidity of the pharmaceutical composition at above 20%.8. The container of claim 7 , wherein the container in combination with the means to keep the equilibrium relative humidity of the pharmaceutical composition at above 20% is capable of maintaining the equilibrium relative humidity of the pharmaceutical composition at above 20% for at least 6 months.9. The container of ...

Подробнее
19-09-2013 дата публикации

Compounds that modulate intracellular calcium

Номер: US20130245025A1
Принадлежит: CalciMedica, Inc.

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. 2. The compound of wherein Ris COH claim 1 , Ris hydrogen claim 1 , and Z is O.3. The compound of wherein J is a bond.4. The compound of wherein A is phenyl.5. The compound of wherein phenyl is substituted with one R.6. The compound of wherein phenyl is substituted with two R.7. The compound of wherein phenyl is substituted with three R.8. The compound of wherein R is selected from F claim 4 , Cl claim 4 , Br claim 4 , I claim 4 , or C-Calkyl.9. The compound of wherein A is benzofuran.10. The compound of wherein benzofuran is substituted with one R.11. The compound of wherein X is B selected from benzoxazole claim 4 , benzothiazole claim 4 , benzimidazole claim 4 , pyrazolopyridine claim 4 , imidazopyridine claim 4 , benzoxadiazole claim 4 , benzothiadiazole claim 4 , and benzotriazole wherein B is optionally substituted with at least one R.12. The compound of wherein B is benzoxazole.13. The compound of wherein B is benzothiazole.14. The compound of wherein B is pyrazolopyridine.15. The compound of wherein B is benzothiadiazole.16. The compound of wherein R is selected from F claim 11 , Cl claim 11 , Br claim 11 , I claim 11 , —CN claim 11 , —NO claim 11 , —CF claim 11 , —OH claim 11 , —OR claim 11 , —OCF claim 11 , C-Calkylenealkyne claim 11 , C-Calkyl claim 11 , C-Ccycloalkyl claim 11 , C-Cheteroalkyl claim 11 , C-Chaloalkyl claim 11 , tetrazolyl claim 11 , C-Cheterocycloalkyl claim 11 , and phenyl.17. The compound of wherein R is selected from F claim 16 , Cl claim 16 , Br claim 16 , and I.19. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable diluent claim ...

Подробнее
19-09-2013 дата публикации

CRYSTALLINE FORMS OF FEBUXOSTAT

Номер: US20130245077A1
Принадлежит: TEVA PHARMACEUTICALS INDUSTRIES LTD.

New forms of Febuxostat have bean, prepared and characterized. These forms are useful for examples in the chronic management of hyperuricemia in patients with gout. 110. A crystalline form of Febuxostat , designated Form F10 , characterized by data selected from one or more of the following: an X-ray powder diffraction pattern having peaks at 6.7° , 7.7° , 12.8° , 13.3° and 20.0°±0.2° 2θ; an X-ray powder diffraction pattern substantially as depicted in ; a solid-state C NMR spectrum with signals at 112.7 , 125.7 , 132.4 and 168.3±0.2 ppm; a solid-state C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 11.7 , 24.7 , 31.4 and 67.3±0.1 ppm; a solid-state C NMR spectrum substantially as depicted in or ; and combinations thereof.2. The crystalline form of Febuxostat claim 1 , designated Form F10 claim 1 , according to claim 1 , characterized by a solid-state C NMR spectrum with signals at 112.7 claim 1 , 125.7 claim 1 , 132.4 and 168.3±0.2 ppm.3. The crystalline form of Febuxostat according to claim 1 , further characterized by an X-ray powder diffraction pattern having peaks at 3.3° claim 1 , 16.3° claim 1 , 16 claim 1 ,9° claim 1 , 24.5° and 25.8°±0.2° 2θ.43. A crystalline form of Febuxostat claim 1 , designated Form F1 claim 1 , characterized by data selected from one or more of the following: a powder XRD pattern with peaks at 5.8° claim 1 , 6.8° claim 1 , 8.1° claim 1 , 11.8° and 17.4°±0.2° 2θ; an XRPD pattern substantially as depicted in ; a solid-state C NMR spectrum with signals at 123.8 claim 1 , 163.1 and 168.5±0.2 ppm; a solid-state C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 23.4 claim 1 , 62.7 and 68.1±0.1 ppm; a solid-state C NMR spectrum substantially as depicted in or ; and combinations thereof.5. The crystalline form ...

Подробнее
19-09-2013 дата публикации

AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES

Номер: US20130245273A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. 2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. The compound according to claim 1 , wherein Ris H or Caliphatic claim 1 , wherein the aliphatic optionally substituted with 1-5 halo.7. The compound according to claim 6 , wherein Ris H or Calkyl claim 6 , wherein the alkyl is optionally substituted with 1-5 halo.8. The compound according to claim 7 , wherein Ris H or Calkyl claim 7 , wherein the alkyl is optionally substituted with 1-5 halo.9. The compound according to claim 8 , wherein the alkyl is methyl claim 8 , ethyl claim 8 , cyclopropyl claim 8 , or isopropyl claim 8 , wherein each alkyl is optionally substituted with 1-5 halo.10. The compound according to claim 6 , wherein the halo is fluoro.11. The compound according to claim 1 , wherein Ris Calkyl.12. The compound according to claim 1 , wherein Ris H.13. The compound according to claim 1 , wherein Ris Calkyl.14. The compound according to claim 1 , wherein Ris H.15. The compound according to claim 1 , wherein Ris H or Calkyl.16. The compound according to claim 15 , wherein Ris methyl.1837-. (canceled) This application is a continuation application of U.S. patent application Ser. No. 12/792,044, filed on Jun. 2, 2010, which is a continuation of International Patent Application No. PCT/US2008/056428, filed on Mar. 10, 2008, which in turn claims the benefit under 35 U.S.C. §119 of U.S. Provisional Patent Application No. 60/905,953, filed on Mar. 9, 2007, as well as U.S. Provisional Patent Application No. 60/953,023, filed on Jul. 31, 2007.The present invention relates to compounds useful as inhibitors of protein kinases. The invention ...

Подробнее
19-09-2013 дата публикации

PROCESS FOR THE PREPARATION OF FEBUXOSTAT

Номер: US20130245278A1
Принадлежит: RANBAXY LABORATORIES LIMITED

An improved and efficient process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) that is substantially free from amide by-product is provided. 2. The process according to claim 1 , wherein the hydrolysis is carried out in the presence of barium oxide.3. The process according to claim 1 , wherein the hydrolysis is carried out in the presence of barium hydroxide octahydrate.5. The process according to claim 4 , wherein febuxostat of Formula I is substantially free of amide by-product.6. The process according to claim 4 , wherein febuxostat of Formula I contains 0.07% amide by-product.7. The process according to claim 4 , wherein in febuxostat of Formula I contains less than 0.07% amide by-product. An improved and efficient process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) that is substantially free from amide by-product is provided.Febuxostat is a non-purine xanthine oxidase inhibitor known from U.S. Pat. No. 5,614,520. It is chemically designated as 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid having the structure as represented by Formula I.Febuxostat is marketed in the United States under the brand name Uloric® and in Europe under the brand name Adenuric® for the chronic management of hyperuricemia in patients with gout. It works by non-competitively blocking the channel leading to the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidate both hypoxanthine and xanthine to uric acid. Hence, febuxostat inhibits xanthine oxidase, therefore, reducing production of uric acid.Processes for the preparation of febuxostat and intermediates thereof are disclosed in U.S. Pat. No. 5,614,520; Japanese Patent Nos. JP 2834971; JP 3202607; JP 2706037, JP 10139770 and JP 3169735.U.S. Pat. No. 5,614,520 discloses preparation of febuxostat by hydrolysis of its corresponding ester using sodium ...

Подробнее
26-09-2013 дата публикации

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

Номер: US20130252937A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of general formula I, 3. A compound according to claim 2 , wherein{'sup': '1', 'Ris selected from the group consisting of a phenyl ring, a 5-membered heteroaromatic ring which contains 2 or 3 heteroatoms independently of each other selected from ═N—, —NH—, —O— and —S—, and a 6-membered heteroaromatic ring which contains 1 or 2 ═N— atoms;'}{'sup': N', '3, 'wherein in said 5-membered heteroaromatic ring the H-atom in one or more NH groups is replaced with Ror R, and'}{'sup': 3', '4, 'wherein each of said phenyl ring, tetrazolyl ring, and heteroaromatic rings is substituted with one group Rand optionally additionally substituted with 1 or 2 substituents independently selected from R;'}{'sup': N', '3', '4, 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein R, Rand Rare defined as in ,'}or a salt thereof.6. A compound according to to claim 2 , wherein{'sup': '3', 'sub': 1-4', '1-4', '3-6, 'Ris selected from the group consisting of C-alkyl, C-alkyl-O—, and C-cycloalkyl-O—,'}{'sup': '5', 'wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 to 3 groups independently selected from Rand optionally substituted with 1 to 3 F atoms;'}or from{'sub': 3', '2', '3, 'C-alkyl-S(═O)— substituted with 1 HO— or HC—O— group; and'}{'sub': 2', '3', '2', '2', '1-3', '1-4', '3-6', '1-4', '2', '2, 'sup': N', 'N', 'N', 'N', 'N, 'heterocyclyl-C(═O)—, HN—C(═O)—, HO—(HC)O—CH—NH—C(═O)—, C-alkyl-NR—C(═O)—, C-alkyl-C(═O)NR—, C-cycloalkyl-C(═O)NR—, heterocyclyl-O(═O)NR—, C-alkyl-S(═O)NR—, heterocyclyl-O—, phenyl-O—, heteroaryl-O—, heterocyclyl-S(═O)—, heterocyclyl, phenyl, and heteroaryl,'}{'sup': '5', 'wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or 2 groups independently selected from Rand optionally substituted with 1 or more F atoms; and'}{'sup': '6', 'wherein each phenyl and heteroaryl ...

Подробнее
26-09-2013 дата публикации

SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY

Номер: US20130253005A1
Принадлежит:

Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents. 3. The pharmaceutical composition of claim 1 , further comprising a DNA cross-linking agent.4. The pharmaceutical composition of claim 1 , further comprising a poly(adenosine diphosphate (ADP)-ribose)polymerase (PARP) inhibitor7. The pharmaceutical composition of claim 5 , further comprising a DNA cross-linking agent.8. The pharmaceutical composition of claim 5 , further comprising a poly(adenosine diphosphate (ADP)-ribose)polymerase (PARP) inhibitor.10. The pharmaceutical composition of claim 9 , further comprising a poly(adenosine diphosphate (ADP)-ribose)polymerase (PARP) inhibitor.11. (canceled)13. (canceled)15. (canceled)1821-. (canceled)2326-. (canceled)2830-. (canceled)32. (canceled)34. (canceled)36. A method to identify a cancer that is responsive to ubiquitin specific protease 1 (USP1) inhibition claim 9 , comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'contacting cancer cells from a cancer with a small molecule inhibitor of USP1 according to Formula I of'}or a pharmaceutically acceptable salt thereof; andmeasuring USP1 activity in the cancer cells contacted with the small molecule inhibitor of USP1,wherein reduced USP1 activity in the cancer cells contacted with the small molecule inhibitor of USP1 relative to control USP1 activity in the cancer cells not contacted with the small molecule inhibitor of USP1 identifies the cancer as a cancer that that is responsive to USP1 inhibition.37. (canceled)38. A method to identify a cancer that is responsive to ubiquitin specific protease 1 (USP1) inhibition claim 9 , comprising{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, 'contacting cancer cells from a cancer with a small molecule inhibitor of USP1 ...

Подробнее
03-10-2013 дата публикации

Inhibition of memapsin 1 cleavage in the treatment of diabetes

Номер: US20130261052A1
Принадлежит: Oklahoma Medical Research Foundation

Proteases such as memapsin-1 are import enzymes, playing roles in a variety of diseases including diabetes. The inventors have developed inhibitors of memapsin 1 and methods of use therefore in the treatment of disease.

Подробнее
10-10-2013 дата публикации

1,4-OXAZEPANE DERIVATIVES

Номер: US20130267494A1
Принадлежит:

Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof. 3. The compound according to claim 2 , wherein ring A is an optionally substituted benzene ring claim 2 , or a salt thereof.7. N-{[(6S claim 2 ,7R)-7-(3 claim 2 ,4-Dichlorophenyl)-1 claim 2 ,4-oxazepan-6-yl]methyl}-2-methoxyacetamide claim 2 , or a salt thereof.8. N-[(6R claim 2 ,7S)-7-(3 claim 2 ,4-Dichlorophenyl)-1 claim 2 ,4-oxazepan-6-yl]acetamide claim 2 , or a salt thereof.9. N-{[(6S claim 2 ,7R)-7-(4-Chloro-3-fluorophenyl)-1 claim 2 ,4-oxazepan-6-yl]methyl}-2-[(H)methyloxy]acetamide claim 2 , or a salt thereof.10. 1-{[(6S claim 2 ,7R)-7-(4-Chloro-3-fluorophenyl)-1 claim 2 ,4-oxazepan-6-yl]methyl}-2-oxo-1 claim 2 ,2-dihydropyridine-3-carboxylic acid claim 2 , or a salt thereof.11. (1S)-1-[(6R claim 2 ,7R)-6-(3 claim 2 ,4-Dichlorophenyl)-1 claim 2 ,4-oxazepan-7-yl]ethane-1 claim 2 ,2-diol claim 2 , or a salt thereof.12. [(7S)-7-(3 claim 2 ,4-Dichlorophenyl)-1 claim 2 ,4-oxazepan-7-yl]methanol claim 2 , or a salt thereof.13. A medicament comprising the compound according to claim 1 , or a salt thereof.14. The medicament according to claim 13 , which is a monoamine reuptake inhibitor.15. The medicament according to claim 13 , which is a prophylactic or therapeutic drug for depression claim 13 , anxiety claim 13 , attention deficit hyperactivity disorder claim 13 , climacteric disorder claim 13 , pain claim 13 , stress urinary incontinence or mixed urinary incontinence.16. A method for the prophylaxis or treatment of depression claim 1 , anxiety claim 1 , attention deficit hyperactivity disorder claim 1 , climacteric disorder claim 1 , pain claim 1 , stress ...

Подробнее
10-10-2013 дата публикации

ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF

Номер: US20130267700A1
Принадлежит: Bayer Intellectual Property GmbH

The present application relates to novel 6-alkylamino-substituted dicyanopyridines, to their amino acid ester prodrugs, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders. 110-. (canceled)12. The compound of claim 11 , wherein{'sup': '1', 'Rrepresents hydrogen, methyl, or ethyl;'}{'sup': '2', 'sub': 1', '3, 'claim-text': {'sub': 1', '3, 'where (C-C)-alkyl may be substituted by 1 or 2 substituents selected independently of one another from the group consisting of fluorine, chlorine, trifluoromethyl, methoxy, ethoxy, cyclopropyl, and cyclobutyl; or'}, 'Rrepresents (C-C)-alkyl, cyclopropyl, or cyclobutyl,'}{'sup': 1', '2, 'claim-text': 'where the 4- to 6-membered heterocycle may be substituted by 1 or 2 substituents selected independently of one another from the group consisting of fluorine, trifluoromethyl, methyl, ethyl, methoxy, and ethoxy;', 'Rand Rtogether with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle which may contain a further heteroatom from the group consisting of N, O, and S,'}{'sup': '4', 'Rrepresents methyl or 3-aminopropan-1-yl;'}{'sup': '5', 'Rrepresents hydrogen;'}{'sup': '6A', 'Rrepresents hydrogen, methyl, or an amino protecting group; and'}{'sup': '7A', 'Rrepresents hydrogen, or an amino protecting group; or'}{'sup': 7A', '4, 'Rtogether with Rand the atoms, to which they are attached, forms a pyrrolidine ring.'}13. The compound of claim 11 , wherein{'sup': '1', 'Rrepresents hydrogen, methyl, or ethyl;'}{'sup': '2', 'Rrepresents methyl, ethyl, or n-propyl, where methyl, ethyl, and n-propyl may be substituted by 1 or 2 substituents selected independently of one another from the group consisting of fluorine, trifluoromethyl, and methoxy; or'}{'sup': 1', '2, 'Rand Rtogether with the nitrogen atom to which ...

Подробнее
24-10-2013 дата публикации

SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES

Номер: US20130281456A1
Принадлежит:

The present invention is directed to a process for preparing a 2,26,6-d-morpholine derivative represented by Structural Formula (I): 110.-. (canceled)12. The compound of claim 11 , wherein the deuterium enrichment at each position designated as deuterium is at least about 85%.13. The compound of claim 12 , wherein R claim 12 , R claim 12 , Rand R are each —H; Ris benzyl; and the deuterium enrichment at each position designated as deuterium is 95%.15. The compound of claim 14 , wherein each of R claim 14 , R claim 14 , Rand R is hydrogen claim 14 , or a salt thereof; and wherein the deuterium enrichment at each position designated as deuterium is at least about 95%.16. The compound of claim 14 , wherein Ris —H claim 14 , benzyl claim 14 , —SO-aryl claim 14 , or —SO-heteroaryl.17. The compound of claim 15 , wherein Ris benzyl.18. The compound of claim 14 , wherein Ris alkyl optionally substituted with one or more groups selected from halogen claim 14 , Calkyl claim 14 , —NO claim 14 , —CN claim 14 , —NH claim 14 , —NHR claim 14 , —N(R) claim 14 , —C(═O)NRR claim 14 , and —SONRR claim 14 , wherein each Calkyl substituent is optionally substituted with one or more groups selected from halogen claim 14 , Calkyl claim 14 , Calkoxy claim 14 , —OH claim 14 , Chaloalkyl and Chaloalkoxy.20. A pyrogen-free pharmaceutical composition comprising the compound of ; and a pharmaceutically acceptable carrier.21. A composition comprising the compound of ; and a pharmaceutically acceptable carrier for use in treating a bacterial infection or a fungal disorder in a subject in need thereof.22Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyrogenes, Enterococcus faecalis, Staphylococcus epidermidis, Staphyloccocus haemolyticusPasteurella multocida.. The composition of claim 21 , wherein the bacterial infection is caused by a bacteria selected from claim 21 , and23Enterococcus faeciumStaphylococcus aureusStreptococcus ...

Подробнее
24-10-2013 дата публикации

COMPOUNDS

Номер: US20130281499A1
Принадлежит:

The present invention relates to substituted triazole compounds of the formula (I): 2. The method according to wherein X represents —CONH— or —CHNH—.3. The method according to wherein Rrepresents phenyl optionally substituted by one claim 1 , two or three groups independently selected from{'sub': 1-6', '3', '1-6', '1-6', '3-6', '3-6, '(a) —Calkyl, —OCH, —Chaloalkyl, —OChaloalkyl, —Ccycloalkyl, —OCcycloalkyl, or halogen;'}(b) phenyl optionally substituted by one, two or three groups independently selected from halogen; and{'sup': '3', 'wherein Rrepresents phenyl optionally substituted by one, two or three groups independently selected from'}{'sub': 1-6', '1-6', '1-6', '2', 'm', '2', 'm', '2', 'n', '2', '2', 'n', '0-6', '2', 'p', '2', 'q', '1-6', '1-6', '1-6', '3-6', '3-6, 'sup': 4', '4', '5', '5', '6', '7', '8', '9, '(a) —Calkyl, —Calkenyl, —Calkoxy, —O(CH)R, —(CH)OC(═O)R, —(CH)COR, —(CH)OC(═O)R, —CalkylOH, —C(═O)NHR, —(CH)NHC(═O)R, —O(CH)NRR, —OCalkylOH, —Chaloalkyl, —OChaloalkyl, —Ccycloalkyl, —OCcycloalkyl or halogen;'}(b) oxazole.4. The method according to wherein Rrepresents —Calkyl.5. The method according to whereinN-[3,4-bis(methyloxy)phenyl]-1-[(4-fluorophenyl)methyl]-5-methyl-1H-1,2,3-triazole-4-carboxamide,N-[3,4-bis(methyloxy)phenyl]-1-[(4-bromophenyl)methyl]-5-methyl-1H-1,2,3-triazole-4-carboxamide,1-[(4-Bromophenyl)methyl]-5-methyl-N-{4-[(phenylmethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,1-[(4-Fluorophenyl)methyl]-5-methyl-N-{4-[(phenylmethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,1-[(4-Fluorophenyl)methyl]-5-methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,1-[(4-Bromophenyl)methyl]-5-methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,5-Methyl-1-(phenylmethyl)-N-{4-[(phenylmethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,5-Methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1-(phenylmethyl)-1H-1,2,3-triazole-4-carboxamide,1-[(2′-Chloro-4-biphenylyl)methyl]-5-methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1H-1,2,3- ...

Подробнее
31-10-2013 дата публикации

PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Номер: US20130289025A1
Принадлежит:

Compounds of the formula I: 123-. (canceled)25. The compound of claim 24 , wherein Ris pyrazolyl optionally substituted with Calkyl claim 24 , halo-Calkyl claim 24 , hetero-Calkyl claim 24 , Calkoxy claim 24 , phenyl claim 24 , heterocyclyl claim 24 , C-cycloalkyl claim 24 , Ccycloalkyl-Calkyl or cyano.26. The compound of claim 24 , wherein Ris pyrazolyl optionally substituted once with Calkyl or halo-Calkyl.27. The compound of claim 24 , wherein Ris phenyl substituted at the 4-position with methyl or halo and optionally substituted at the 2- and 6-positions with halo.28. The compound of claim 24 , wherein Ris 4-methyl-phenyl claim 24 , 2-fluoro-4-methyl-phenyl claim 24 , 2-chloro-4-fluoro-phenyl claim 24 , 4-chloro-2-fluoro-phenyl claim 24 , 2 claim 24 ,4-dichloro-phenyl claim 24 , 2 claim 24 ,4-difluoro-phenyl claim 24 , or 2-chloro-4-methyl-phenyl.29. The compound of claim 24 , wherein Ris pyridin 2-yl substituted with methyl or halo at the 5-position and optionally substituted with halo at the 3-position.30. The compound of claim 24 , wherein Ris 5-methyl-pyridin-2-yl claim 24 , 5-chloro-pyridin-2-yl claim 24 , 5-fluoro-pyridin-2-yl claim 24 , 5-methyl-3-fluoro-pyridin-2-yl claim 24 , 5-methyl-3-chloro-pyridin-2-yl claim 24 , 3 claim 24 ,5-difluoro-pyridin-2-yl or 3 claim 24 ,5-dichloro-ppyridin-2-yl.31. The compound of claim 24 , wherein R claim 24 , Rand Rare hydrogen.32. The compound of claim 24 , wherein Ris hydrogen.33. The compound of claim 24 , wherein Ris hydrogen.34. The compound of claim 24 , wherein Ris methyl.35. The compound of claim 24 , wherein Rand Rtogether with the atom to which they are attached form a Ccarbocyclic ring that is optionally substituted with hydroxy.36. The compound of claim 24 , wherein Ris: Calkyl; Calkyloxy-Calkyl; hydroxy-Calkyl; Calkylsulfanyl-Calkyl; Calkylsulfonyl-Calkyl; amino-Calkyl; N—Calkyl-amino-Calkyl; N claim 24 ,N-di-Calkyl-amino-Calkyl; Ccycloalkyl; optionally substituted phenyl; heteroaryl claim 24 , or ...

Подробнее
31-10-2013 дата публикации

HETEROCYCLIC FUSED ANTHRAQUINONE DERIVATIVES, MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION USING THEREOF

Номер: US20130289028A1
Принадлежит: NATIONAL DEFENSE MEDICAL CENTER

A heterocyclic fused anthraquinone derivatives, which is represented by a formula (I): 2. The heterocyclic fused anthraquinone derivatives of claim 1 , wherein Ris aminoalkyl group claim 1 , sulfoalkyl group or haloalkyl group claim 1 , the alkyl group can be selected from the group consisting of Cstraight-chain alkyl group claim 1 , Cbranched alkyl group and Ccyclic alkyl group claim 1 , and the halogens can be selected from the group consisting of F claim 1 , Cl claim 1 , Br and I.3. The heterocyclic fused anthraquinone derivatives of claim 2 , wherein Ris Cl claim 2 , sulfonic acid sodium claim 2 , oxide potassium claim 2 , diethylamino group claim 2 , amino-propyl group claim 2 , amino-cyclobutyl group claim 2 , amino-dimethyl group claim 2 , amino-ethyl group claim 2 , ethyl piperazino group claim 2 , amimo-cyclopentylamino group claim 2 , amino-butylamino group claim 2 , amino-ethylamino claim 2 , amino-2-methylpropylamino group claim 2 , thio-morpholino group claim 2 , thio-ethyl group claim 2 , thio-n-propyl group or thio-isopropyl group.4. The heterocyclic fused anthraquinone derivatives of claim 1 , wherein the Ris amino group and the Ris 3-chlorophenylamino group claim 1 , 2-methylphenylamino group claim 1 , 3-methylphenylamono group claim 1 , 4-methylphenylamino group claim 1 , 4-chlorophenylamino group or 4-chloro-2-fluorophenylamino group.5. The heterocyclic fused anthraquinone derivatives of claim 1 , wherein the Ris oxygen and Ris para-methylphenyl-oxy group.6. The heterocyclic fused anthraquinone derivatives of claim 1 , wherein the Ris sulfur group and Ris phenylthio claim 1 , 2 claim 1 ,5-dimethylphenylthio group claim 1 , benzylthio group claim 1 , 4-chlorophenylthio group claim 1 , 2-methylphenylthio group claim 1 , 4-bromophenylthio group claim 1 , 2 claim 1 ,4-dimethylphenylthio group claim 1 , 4-isopropylphenylthio group claim 1 , 2-bromophenylthio group claim 1 , 4-fluorophenylthio group claim 1 , phenylthioethyl group claim 1 , 2 claim 1 ,3 ...

Подробнее
31-10-2013 дата публикации

N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE

Номер: US20130289057A1
Принадлежит:

The invention relates to N-arylaminomethylenebenzothiophenones of General Formula (I) for use as a drug for the treatment of cardiovascular diseases: 2. The method of claim 1 , wherein Ar is an aromatic pentacycle with at least nitrogen as a ring member.3. The method of claim 2 , wherein said aromatic pentacycle is substituted by hydrogen only claim 2 , or by hydrogen and one electron-withdrawing group selected from the group consisting of halogen claim 2 , a carboxylic acid or its C1-C4 alkyl ester claim 2 , a carboxylic acid amide claim 2 , carboxamidine claim 2 , a nitrile claim 2 , isonitrile claim 2 , cyanate claim 2 , isocyanate claim 2 , thiocyanate claim 2 , isothiocyanate claim 2 , a nitro group claim 2 , and a mono- claim 2 , di- or trifluoromethane group.4. The method of claim 1 , wherein Ar is selected from Table 1 column A.5. The method of claim 1 , wherein Ar is selected from Table 1 column B.7. The compound of claim 6 , wherein the pentacyclic heteroaryl moiety is substituted by one or more substituents selected from the group consisting of a halogen claim 6 , a carboxylic acid or its C1- claim 6 , C2- claim 6 , C3- or C4 alkyl ester claim 6 , a carboxylic acid amide claim 6 , carboxamidine claim 6 , a nitrile claim 6 , isonitrile claim 6 , cyanate claim 6 , isocyanate claim 6 , thiocyanate claim 6 , isothiocyanate claim 6 , a nitro group or a mono- claim 6 , di- or trifluoromethane group claim 6 , and a C1- claim 6 , C2- claim 6 , C3- or C4 alkoxide moiety.8. A method for the treatment of cardiovascular diseases claim 6 , comprising:{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, 'administering to a patient in need of such treatment a composition comprising the compound of .'}9. The method of claim 8 , wherein the pentacyclic heteroaryl moiety is substituted by one or more substituents selected from the group consisting of a halogen claim 8 , a carboxylic acid or its C1- claim 8 , C2- claim 8 , C3- or C4 alkyl ester claim 8 , a carboxylic acid ...

Подробнее
07-11-2013 дата публикации

PURIFICATION METHOD OF AZTREONAM

Номер: US20130296549A1
Автор: Tao Linggang
Принадлежит:

It discloses a process for refining Aztreonam, comprising the steps of 1) treating Aztreonam material with an alkali metal alkoxylate or an alkali earth metal alkoxylate under heating in the presence of a suitable solvent or a mixture of solvents, followed by adjusting the pH value with a suitable acid and cooling down to precipitate Aztreonam, which provides a primary purified Aztreonam; 2) adsorbing Aztreonam with strongly basic ion exchange resin, followed by eluting the resin and collecting the eluate, to provide a secondary purified Aztreonam after concentration under reduced pressure; 3) adjusting the pH value with a suitable acid to allow crystallization, followed by centrifuging and washing the resultant crystals, to provide a tertiary purified Aztreonam after drying. The refined Aztreonam product has a purity of no less than 99.2%, mostly no less than 99.5%, with little residue on ignition and significantly low content of heavy metals. 1. A process for refining Aztreonam comprising the following steps:1) treating a crude Aztreonam with an alkali metal alkoxylate or an alkali earth metal alkoxylate with a heat in a suitable solvent or a mixture of solvents, then adjusting pH with a suitable acid and cooling to precipitate Aztreonam which yields a primary purified Aztreonam;2) loading the primary purified Aztreonam into a strongly basic ion exchange resin, then eluting the resin and collecting eluate which is concentrated by a reduced pressure to yield a secondary purified Aztreonam; and3) adjusting pH value with a suitable acid to allow crystallization, then centrifuging, washing and drying the resultant crystals to yield a tertiary purified Aztreonam.2. The process for refining Aztreonam according to claim 1 , wherein said heat adjusts the temperature at a range between 30° C. and 100° C.3. The process for refining Aztreonam according to claim 1 , characterized in that claim 1 , the alkali metal alkoxylate is preferably an alkoxylate of potassium or sodium ...

Подробнее
14-11-2013 дата публикации

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES

Номер: US20130303515A1
Принадлежит:

Compounds are disclosed that have a formula represented by the following: 3. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein Y is Me claim 1 , Et claim 1 , Pr claim 1 , iPr claim 1 , or —CH-Ph.5. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein Ris —(CH)—COOH claim 1 , —(CH)—COOH claim 1 , —(CH)—SONH claim 1 , or —(CH)—SONHMe.6. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein Cyis phenyl claim 1 , or naphthalene.7. A compound or pharmaceutically acceptable salt thereof claim 1 , according to claim 1 , wherein Cyis thiophenyl claim 1 , benzothiophenyl claim 1 , benzofuranyl claim 1 , benzoisoxazolyl claim 1 , benzoxazolyl or indolyl.8. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 1 or 2.9. A compound or pharmaceutically acceptable salt thereof according to claim 8 , wherein each Rgroup is independently selected from F claim 8 , Cl claim 8 , Br claim 8 , Me claim 8 , CF claim 8 , and OMe.10. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein m is 0.11. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein Lis a single bond.12. A compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein Lis —CH—.13. A compound according to claim 1 , wherein the compound is 4-[[(R)-1-(Benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-(3-chloro-benzyl)-amino]-butyric acid; or a pharmaceutically acceptable salt claim 1 , or a solvate claim 1 , or a solvate of the pharmaceutically acceptable salt.14. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof claim 1 , according to claim 1 , and a pharmaceutically acceptable carrier.15. The pharmaceutical composition according to comprising a further therapeutic agent.16. (canceled)17. A method for the treatment of inflammatory conditions claim 1 ...

Подробнее
14-11-2013 дата публикации

PROCESS FOR THE PREPARATION OF DIOL SULFONES

Номер: US20130303779A1

The present invention relates to a process for the preparation of a diol sulfone derivative comprising reaction of a halomethyl substrate with a thio-aryl compound to obtain a thio-ether compound, and oxidizing the thio-ether compound to the corresponding sulfone. In case of a chiral halomethyl substrate, the resulting chiral diol sulfone derivative is suitable as a building block for statin type compounds. 2. Process according to wherein Ris bromine or chlorine claim 1 , Ris ethyl or methyl and Ris ethyl or methyl or Rand Rform a cyclopentyl ring or a cyclohexyl ring together with the carbon atom to which they are bound claim 1 , Ris tert-butyl claim 1 , ethyl claim 1 , methyl claim 1 , or iso-propyl claim 1 , Ris methoxyethoxymethyl claim 1 , tetrahydrofuranyl or tetrahydropyranyl and Ris 1-methyl-1H-tetrazol-5-yl claim 1 , 1-phenyl-1H-tetrazol-5-yl claim 1 , 1-tert-butyl-1-H-tetrazol-5-yl claim 1 , benzothiazol-2-yl or 3 claim 1 ,5-bis(trifluoromethyl)phenyl-1-yl.3. Process according to wherein said compound of general formula (3a) or (3b) is isolated and/or wherein said compound of general formula (4a) or (4b) is isolated.4. Process according to wherein said oxidation is carried out in the presence of hydrogen peroxide or a peracid or bleach or tert-BuOCl or a perborate or an N-oxide or a permanganate or a chromate or a chlorate or a bromate or a perchlorate or a periodate or tert-butyl hydroperoxide or oxone or a peroxodisulfate or oxygen or mixtures thereof.6. Process according to carried out in the presence of a sodium-comprising base.7. Process according to wherein said sodium-comprising base is sodium hexamethyldisilazane.8. Process according to followed by deprotection and isolation.10. Compound according to wherein Ris chosen from the group consisting of pyridine-2-yl claim 9 , pyrimidin-2-yl claim 9 , benzothiazol-2-yl claim 9 , 1-methyl-1H-tetrazol-5-yl claim 9 , 1-phenyl-1H-tetrazol-5-yl claim 9 , 1-tert-butyl-1-H-tetrazol-5-yl claim 9 , 1- ...

Подробнее
14-11-2013 дата публикации

PROCESS FOR THE PREPARATION OF 2-ARYLTHIAZOLE DERIVATIVES

Номер: US20130303780A1
Принадлежит:

The present invention relates an improved process for the preparation of 2-arylthiazole derivatives which are intermediates of Febuxostat and further conversion to Febuxostat or pharmaceutically acceptable salts thereof. 2. The process according to claim 1 , wherein the organic solvent is selected from the group consisting of dimethyl sulfoxide claim 1 , dimethylacetamide claim 1 , dimethyl formamide and acetonitrile.3. The process according to claim 1 , wherein the acyl halide is selected from the group consisting of acetyl bromide and acetyl chloride.4. The process according to claim 1 , wherein the sulfonyl chloride is selected from the group consisting of methane sulfonyl chloride and para-toluene sulfonyl chloride.5. The process according to claim 1 , wherein the base is an alkali metal carbonate.6. The process according to claim 1 , wherein the compound of formula-II is further hydrolyzed to Febuxostat or a pharmaceutically acceptable salts thereof.7. The process according to claim 6 , wherein the compound of formula-II is hydrolyzed by using aqueous ethanol claim 6 , aqueous methanol claim 6 , aqueous acetone claim 6 , aqueous acetonitrile or aqueous isopropyl alcohol.10. (canceled)12. The process according to claim 5 , wherein the alkali metal carbonate is potassium carbonate or sodium carbonate. This application claims priority to Indian patent application No. 3312/CHE/2010 filed on Nov. 4, 2010.The present invention relates an improved process for the preparation of 2-Arylthiazole derivatives which are intermediates of Febuxostat and further conversion to Febuxostat or pharmaceutically acceptable salts thereof.2-Arylthiazole derivatives are used as xanthine oxidase inhibitors for use in the treatment of hyperuricemia and gout.Febuxostat, 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid of Formula-I is an example of 2-arylthiazole derivatives used as xanthine oxidase inhibitors for use in the treatment of hyperuricemia and gout.Febuxostat ...

Подробнее
28-11-2013 дата публикации

Benzothiazole Derivatives

Номер: US20130317219A1
Принадлежит: BIOTIE THERAPIES, INC.

Provided are compounds and their pharmaceutically acceptable salts that are useful for the treatment of diseases related to the adenosine receptor. Also included are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance. This application is a continuation of U.S. application Ser. No. 13/377,811 issuing as U.S. Pat. No. 8,501,938 on Aug. 6, 2013 which was a 35 USC §371 national stage entry of PCT/US2010/038868, filed Jun. 16, 2010, and claims the benefit of U.S. application Ser. No. 12/486,457, filed on Jun. 17, 2009, all of which, are hereby incorporated by reference in their entireties for all purposes.The present invention is related to benzothiazole compounds, and more particularly to benzothiazole derivatives showing activity as adenosine receptor ligands.Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzyme A; and to RNA. Together adenosine and these related compounds are important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities.The receptors for adenosine have been classified as A, A, Aand Areceptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent on the receptor associated G protein. Each of the adenosine receptor subtypes has been classically characterised by the adenylate cyclase ...

Подробнее
05-12-2013 дата публикации

NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES

Номер: US20130324719A1
Принадлежит: Lee Pharma Limited

A novel process for preparing oxazolidinone antibacterial agent Linezolid including key intermediates of oxazolidinones comprising: reacting 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin; carbonylation to form oxazolidinone derivative; acetylation of (5R)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl-oxazolidin-2-one with sodium acetate to get novel intermediate; hydrolysis of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate; mesylation of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol; reaction of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl methane sulphonate with potassium phthalimide; hydrolysis of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide with hydrazine hydrate; acetylation of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl amine with acetic anhydride yields Linezolid in high yield. 2. The process according to claim 1 , wherein the quantity of epichlorohydrin is at least 1.25 molar equivalent per equivalent of formula IX.3. The process according to claim 1 , wherein the reaction in step (a) is carried out with use of a solvent and at 70-80° C.4. The process according to claim 3 , wherein the solvent is tertiary butanol.5. The process according to claim 1 , wherein chloromethyl oxazolidinone is crystallized from an organic solvent.6. The process according to claim 5 , wherein the solvent is selected from ethylacetate and n-butyl acetate7. The process according to claim 6 , wherein the solvent is n-butyl acetate.9. The process according to claim 8 , wherein the quantity of sodium acetate is at least 2.0 molar equivalents to compound of formula VII.10. The process according to claim 8 , wherein the reaction solvent is selected from aprotic solvent.11. The process according to claim 10 , wherein the reaction solvent is DMF.12. The process according to claim 8 , wherein the reaction is carried out at a temperature of 120° C.14. The process ...

Подробнее
05-12-2013 дата публикации

GLUTAMIC ACID BENZYL ESTER N-CARBOXYLIC ANHYDRIDE

Номер: US20130324739A1
Принадлежит: NIPPON SODA CO., LTD.

An object of the present invention is to provide crystal polymorphs which have a high bulk density and are excellent in storage stability, among crystal polymorphs of a glutamic acid benzyl ester N-carboxylic anhydride. According to the present invention, the crystal polymorphs of glutamic acid benzyl ester N-carboxylic anhydride that have a bulk density of 0.45 g/cmor higher can be obtained by dissolving glutamic acid benzyl ester N-carboxylic anhydride in a solvent which has been heated at a temperature equal to or higher than 40° C. and lower than a boiling point thereof and is in an amount of 0.5 L or more per mol of the glutamic acid benzyl ester N-carboxylic anhydride, adding a poor solvent which is in an amount of 1.4 L or more per mol of the glutamic acid benzyl ester N-carboxylic anhydride at a temperature equal to or higher than 40° C. and lower than a boiling point thereof, precipitating crystals at a temperature equal to or higher than 40° C. and lower than a boiling point thereof, and cooling the crystals. 1. A glutamic acid benzyl ester N-carboxylic anhydride that includes crystal polymorphs (crystals A) having peaks at 6.5° , 13.0° , and 19.5° at an angle of diffraction (2 θ°) in a powder X-ray diffraction diagram using CuKα rays as an X-ray source and has a bulk density of 0.45 g/cmor greater.2. The glutamic acid benzyl ester N-carboxylic anhydride according to that includes the crystals A claim 1 ,wherein the crystals A differ from each other in terms of preferred orientation and have peaks at 15.0°, 17.3°, 18.9°, 19.9°, 21.2°, 23.2°, 23.9°, 25.0°, and 27.7° at an angle of diffraction (2 θ°) in a powder X-ray diffraction diagram using CuKα rays as an X-ray source.3. A method for crystallizing a glutamic acid benzyl ester N-carboxylic anhydride claim 1 , comprising:dissolving glutamic acid benzyl ester N-carboxylic anhydride in a solvent which has been heated at a temperature equal to or higher than 40° C. and lower than a boiling point thereof and ...

Подробнее
19-12-2013 дата публикации

DEOXYCYTIDINE KINASE BINDING COMPOUNDS

Номер: US20130336883A1

The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission tomography (PET) imaging. 2. The compound of claim 1 , wherein R1 and R2 are independently H claim 1 , NH2 claim 1 , NHC(O)R15 or NHC(O)OR17; or a salt thereof.3. The compound of claim 2 , wherein each R1 and R2 is NH2; or a salt thereof.4. The compound of claim 2 , wherein each R1 and R2 is NHC(O)R15; or a salt thereof.5. The compound of claim 4 , wherein R15 is CH3; or a salt thereof.6. The compound of claim 4 , wherein R15 is CF3; or a salt thereof.7. The compound of claim 1 , wherein R5 is F claim 1 , Cl claim 1 , Br claim 1 , I claim 1 , CF3 claim 1 , fluoropyridyl or OR10; or a salt thereof.8. The compound of claim 7 , wherein R5 is OR10; or a salt thereof.9. The compound of claim 8 , wherein R10 is C1-C6 alkyl claim 8 , C1-C6 perfluoroalkyl claim 8 , (CH2)mX claim 8 , (CH2)pOR12 or (CH2)rX*; or a salt thereof.10. The compound of claim 9 , wherein R10 is (CH2)rX*; or a salt thereof.11. The compound of claim 10 , wherein X* is 18F; or a salt thereof.12. The compound of claim 1 , wherein the compound binds to a deoxycytidine kinase polypeptide.13. The compound of claim 1 , or a salt thereof claim 1 , and a pharmaceutically acceptable carrier.14. A method for inhibiting a dexoycytidine kinase (dCK) activity comprising contacting a compound of with the dexoycytidine kinase.17. The method of claim 16 , whereincontacting the compound with a biological material comprises administering a quantity of the compound to an animal or human; andcorrelating the local concentration of the compound in the animal or human with a local immune response or neoplastic tissue in the animal or human.18. The ...

Подробнее
19-12-2013 дата публикации

PARASITE- AND HYGIENIC PEST-CONTROLLING AGENT

Номер: US20130338197A1
Принадлежит: NISSAN CHEMICAL INDUSTRIES, LTD.

There is provided a novel agent for controlling harmful arthropods or nematodes that are parasites and hygienic pests for animals. An ecto- or endo-parasiticide for mammals or the like comprising as active ingredient, one or more selected from substituted benzamide compounds of formula (1) or salts thereof: 4. The method according to claim 3 , wherein in the parasite- and hygienic pest-controlling composition claim 3 ,{'sup': 3', '4, 'Aand Aare C—H,'}W is oxygen atom,{'sup': '1', 'Xis chlorine atom, bromine atom, iodine atom or trifluoromethyl,'}{'sup': '2', 'Xis hydrogen atom, halogen atom or trifluoromethyl,'}{'sup': '3', 'Xis hydrogen atom, fluorine atom or chlorine atom,'}{'sup': '1', 'Yis halogen atom, nitro, methyl, ethyl or trifluoromethyl,'}{'sup': '1', 'Ris trifluoromethyl,'}{'sup': '1a', 'Ris hydrogen atom,'}{'sup': '3', 'Ris hydrogen atom, and'}m is 0.5. The method according to claim 4 , wherein in the parasite- and hygienic pest-controlling composition claim 4 ,{'sup': 1', '3, 'Ais C—X,'}{'sup': '1', 'Xis chlorine atom, bromine atom or trifluoromethyl,'}{'sup': '2', 'Xis chlorine atom, bromine atom or trifluoromethyl,'}{'sup': '3', 'Xis hydrogen atom or fluorine atom,'}{'sup': '1', 'Yis chlorine atom, bromine atom or methyl, and'}{'sup': '2', 'Ris E-3.'}6. The method according to claim 1 , wherein in the parasite- and hygienic pest-controlling composition claim 1 ,G is a heterocyclic ring of G-1, and{'sup': '2', 'Ris E-3.'}7. The method according to claim 1 , wherein in the parasite- and hygienic pest-controlling composition claim 1 ,G is a heterocyclic ring of G-1, and{'sup': '2', 'Ris E-6.'}8. The method according to claim 1 , wherein in the parasite- and hygienic pest-controlling composition claim 1 ,G is a heterocyclic ring of G-2,{'sup': 1a', '1b, 'Rand Rare hydrogen atom, and'}{'sup': '2', 'Ris E-3.'}9. The method according to claim 1 , wherein in the parasite- and hygienic pest-controlling composition claim 1 ,G is a heterocyclic ring of G-2,{'sup ...

Подробнее
19-12-2013 дата публикации

Compounds for the treatment of neurodegenerative diseases

Номер: US20130338202A1
Принадлежит: Proteo Tech Inc

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

Подробнее
26-12-2013 дата публикации

Phenoxy thiophene sulfonamides and other compounds for use as inhibitors of bacterial glucuronidase

Номер: US20130345196A1

This invention relates generally to compounds that are glucuronidase inhibitors. The glucuronidase inhibitors include phenoxy thiophene sulfonamides, and other compounds such as pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls. These compounds include nialamide, isocarboxazid, phenelzine, amoxapine, loxapine and mefloquine. Also compositions including one or more of such compounds for use in inhibiting glucuronidase and methods of using one or more of such compounds for selective inhibition of bacterial β-glucuronidase. These compounds may be used as a co-drug in combination with the anticancer drug CPT-11. Also a method for screening compounds to determine their usefulness in reducing diarrhea associated with irinotecan chemotherapy.

Подробнее
26-12-2013 дата публикации

PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE

Номер: US20130345235A1
Принадлежит:

This invention relates generally to compounds that are glucuronidase inhibitors. Glucuronidase inhibitors described include phenoxy thiophene sulfonamides. Other compounds, for instance pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls, are also contemplated. Also contemplated are compositions including one or more of such compounds for use inhibiting glucuronidase and methods of using one or more of such compounds as a co-drug to be used in combination with the anticancer drug CPT-11. 2. A method of treating a subject in need of a glucuronidase inhibitor comprising administering to the subject a composition comprising an amount of compound that is effective as an inhibitor of glucuonidase activity , or a pharmaceutically acceptable salt of the compound.3. The method of claim 2 , wherein the compound is selected from one or more of phenoxy thiophene sulfonamides claim 2 , pyridine sulfonyls claim 2 , benzene sulfonyls claim 2 , thiophene sulfonyls claim 2 , thiazole sulfonyls claim 2 , thiophene carbonyls claim 2 , and thiazole carbonyls.5. A compound that is an inhibitor of glucuronidase claim 2 , or a pharmaceutically acceptable salt of the compound. claim 2 , wherein the compound is chosen from one or more of phenoxy thiophene sulfonamides claim 2 , pyridine sulfonyls claim 2 , benzene sulfonyls claim 2 , thiophene sulfonyls claim 2 , thiazole thiophene carbonyls claim 2 , and thiazole carbonyls.6. A composition comprising a compound according to and one or more pharmaceutically acceptable carriers claim 5 , diluents and excipients.8. The method of for making a compound of formula (I) wherein:{'sub': '1', '(a) the halothiophene sulfonyl halo is dichlorothiophene-sulfonyl chloride and the group R—N—H is naphthylmethylamine, and the dichlorothiophene-sulfonyl chloride and naphthylmethylamine, are mixed and cooled, thereby forming a N-monoprotected thiophene sulfonamide, having a first N- ...

Подробнее
26-12-2013 дата публикации

DIHYDROOXAZOL-2-AMINE DERIVATIVES

Номер: US20130345241A1
Принадлежит: Hoffmann-La Roche Inc.

The invention relates to compounds of formula 3. The compound of claim 2 , wherein Ar is selected from pyridinyl claim 2 , pyridazinyl claim 2 , pyrimidinyl claim 2 , pyrazinyl and quinolinyl.6. The compound of claim 3 , selected from the group consisting of{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(6-chloro-pyrimidin-4-yl)-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(6-methoxy-pyrimidin-4-yl)-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(2-methyl-pyrimidin-4-yl)-amine;(S)-4-(4-(Pyrimidin-4-ylamino)phenethyl)-4,5-dihydrooxazol-2-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(4-methoxy-pyrimidin-2-yl)-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(5-ethyl-pyrimidin-2-yl)-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(5-methoxy-pyrimidin-2-yl)-amine;5-{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenylamino}-pyrazine-2-carbonitrile;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(4-trifluoromethyl-pyrimidin-2-yl)-amine; and{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(3-chloro-pyrazin-2-yl)-amine.8. The compound of claim 3 , selected from the group consisting of{4-[2-((4S,5S)-2-Amino-5-methyl-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(5-chloro-pyrimidin-2-yl)-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(5-cyclopropyl-pyrimidin-2-yl)-amine;{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-(5-ethoxy-pyrimidin-2-yl)-amine;(S)-4-(4-(5-(Trifluoromethyl)pyrimidin-2-ylamino)phenethyl)-4,5-dihydrooxazol-2-amine;(S)-4-(4-(5-tert-Butylpyrimidin-2-ylamino)phenethyl)-4,5-dihydrooxazol-2-amine;(S)-4-(4-(5-(Pentan-3-yl)pyrimidin-2-ylamino)phenethyl)-4,5-dihydrooxazol-2-amine;2-{4-[2-((S)-2-Amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenylamino}-pyrimidine-5-carbonitrile;(S)-4-(4-(5-Cyclobutylpyrimidin-2-ylamino)phenethyl)-4,5-dihydrooxazol-2-amine;(S)-4-(4-(5-Isopropylpyrimidin-2-ylamino)phenethyl)-4,5-dihydrooxazol ...

Подробнее
02-01-2014 дата публикации

2-AMINOTHIAZOLE DERIVATIVES AND METHODS OF PREPARING AND USING THE SAME

Номер: US20140004155A1
Принадлежит:

2-aminothiazole derivatives represented by formula (I), where Rand Rrepresent cycloalkyls, respectively; or Rrepresents a substituted aromatic group, and Rrepresents H, a C-Calkyl, —CHPh (benzyl), or a methyl ether including a C-Calkyl. Ris a substituent including an amino group. X represents a carbonyl or a methylene and n is an integer from 0 to 5. 2. The compound of claim 1 , wherein the cycloalkyl is a cyclic hydrocarbon comprising between 3 and 7 rings.5. The compound of claim 1 , wherein X represents the methylene claim 1 , Ris a pyridine claim 1 , 3-indole claim 1 , or 4-imidazole; and n=0.6. A method for preparing the compound of claim 1 , the method comprising:a) substituting hydroxyl radicals of diethanolamine by a halogen to yield bis (2-dichloroethyl) amine hydrochloride;b) allowing bis(2-dichloroethyl) amine hydrochloride and a substituted aromatic amine to react in the presence of microwave or in general reaction conditions to yield a substituted aromatic piperazine (an intermediate (1));c) heating a substituted methyl aromatic ketone and a substituted thiourea in the presence of iodine molecules to perform reaction to yield a 2-aminothiazole derivative (an intermediate (2));d) substituting the 2-aminothiazole derivative (the intermediate (2)) by a halogenated acyl halide to yield a ω-halogenated amide derivative (an intermediate (3)); ande) allowing the intermediate (1) to react with the intermediate (3) to yield the 2-aminothiazole derivative comprising a heterocycle; or allowing the intermediate (3) to react with a benzylamine to yield a product, and allowing the product to react with a corresponding halohydrocarbon to yield the 2-aminothiazole derivative comprising a general amino; or performing a condensation reaction between the intermediate (2) and a substituted aldehyde compound catalyzed by an alkali to yield the 2-aminothiazole derivative comprising methylene.7. A method for treatment of Alzheimer's disease and a neurodegenerative disease ...

Подробнее
02-01-2014 дата публикации

POSITIVE PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE AND LIQUID CRYSTAL DISPLAY DEVICE

Номер: US20140005409A1
Принадлежит: FUJIFILM Corporation

A compound represented by the following formula (I): 4. The compound according to claim 1 , wherein Rin formula (I) is a cyano group.5. The compound according to claim 1 , wherein Rin formula (I) is an aryl group.6. The compound according to claim 5 , wherein the aryl group is a phenyl group or a naphthyl group. This application is a divisional application of application Ser. No. 13/180,564, filed Jul. 12, 2011, which is based upon and claims the benefit of priority from prior Japanese Patent Application No. 2010-185625, filed Aug. 20, 2010. The entire contents of these applications are incorporated herein by reference in their entirety.1. Technical FieldThe present invention relates to a positive photosensitive resin composition, a method for forming a cured film, a cured film, an organic EL display device including the cured film and a liquid crystal display device including the cured film.2. Related ArtOrganic EL display devices, liquid crystal display devices and the like include a patterned interlayer dielectric film. In order to form an interlayer dielectric film, a photosensitive resin composition is widely used from the viewpoint of reducing the number of processes for obtaining an intended pattern shape and achieving sufficient flatness.In addition to physical properties such as favorable insulation properties, solvent resistance, thermal resistance, hardness and suitability for indium tin oxide (ITO) sputtering, there is a demand for an interlayer dielectric film used in the display devices as mentioned above to exhibit high transparency. Thus, use of an acrylic resin, which is highly transparent, as a component for forming a film has been attempted.Further, with regard to a light source for exposing a photosensitive resin composition to light, as a direct drawing method by exposure to 355 nm laser light, use of various light sources in pattern formation, such as g and h line-mixed light sources from which i line is excluded, in addition to conventionally ...

Подробнее
09-01-2014 дата публикации

DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Номер: US20140011782A1
Принадлежит:

Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations. 153-. (canceled)54. A method for the treatment of a disorder selected from Duchenne muscular dystrophy , Becker muscular dystrophy , and cachexia , comprising administering to a patient that has been diagnosed with said disorder an effective amount of:a) the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, wherein said patient is undergoing treatment with a corticosteroid;b) a corticosteroid, wherein said patient is undergoing treatment with the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof; orc) a combination of the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole, or a pharmaceutically acceptable salt thereof, and a corticosteroid.55. A method according to claim 54 , wherein said method comprises administering to a patient the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole claim 54 , or a pharmaceutically acceptable salt thereof claim 54 , wherein said patient is undergoing treatment with a corticosteroid.56. A method according to claim 54 , wherein said method comprises administering to a patient a corticosteroid claim 54 , wherein said patient is undergoing treatment with the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole claim 54 , or a pharmaceutically acceptable salt thereof.57. A method according to claim 54 , wherein said method comprises administering to a patient the combination of the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole claim 54 , or a ...

Подробнее
09-01-2014 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20140011997A1
Принадлежит: THERAVANCE, INC.

In one aspect, the invention relates to compounds having the formula: 1. (canceled)2. The process of claim 18 , where X is selected from pyrazole claim 18 , imidazole claim 18 , triazole claim 18 , benzotriazole claim 18 , furan claim 18 , pyrrole claim 18 , tetrazole claim 18 , pyrazine claim 18 , thiophene claim 18 , oxazole claim 18 , isoxazole claim 18 , thiazole claim 18 , isothiazole claim 18 , oxadiazole claim 18 , thiadiazole claim 18 , pyridazine claim 18 , pyridine claim 18 , pyrimidine claim 18 , pyran claim 18 , benzimidazole claim 18 , benzoxazole claim 18 , benzothiazole claim 18 , pyridylimidazole claim 18 , and pyridyltriazole.3. The process of claim 2 , where X is selected from pyrazole claim 2 , triazole claim 2 , benzotriazole claim 2 , tetrazole claim 2 , oxazole claim 2 , isoxazole claim 2 , thiazole claim 2 , pyridazine claim 2 , pyrimidine claim 2 , and pyridyltriazole.4. The process of claim 18 , where Ris selected from —ORand —NRR claim 18 , where Ris H claim 18 , Ris H or —OH claim 18 , and Ris H.7. The process of claim 18 , where Ris H.8. The process of claim 18 , where Ris absent or is selected from H; halo; —Calkylene-OH; —NH; —Calkyl; —CF; —Ccycloalkyl; —Calkylene-O—Calkyl; —C(O)R; —Calkylene-COOR; —C(O)NRR; —NHC(O)R; ═O; —NO; —C(CH)═N(OH); phenyl optionally substituted with one or two groups independently selected from halo claim 18 , —OH claim 18 , —CF claim 18 , —OCH claim 18 , —NHC(O)CH claim 18 , and phenyl; naphthalenyl; pyridinyl; pyrazinyl; pyrazolyl optionally substituted with methyl; thiophenyl optionally substituted with methyl or halo; furanyl; and —CH-morpholinyl; and Ris H.10. The process of claim 18 , where Ris absent or is selected from H; halo; —Calkylene-OH; —Calkyl; —Ccycloalkyl; —Calkylene-O—Calkyl; —C(O)R; —Calkylene-COOR; —C(O)NRR; —NHC(O)R; —NHC(O)R; ═O; phenyl optionally substituted with one or two groups independently selected from halo claim 18 , —OH claim 18 , and —OCH; pyridinyl; and pyrazinyl; Ris —Calkyl; ...

Подробнее
09-01-2014 дата публикации

METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF

Номер: US20140012010A1
Принадлежит:

Provided is a process for producing an optically active compound represented by Formula (3): 2. The production process according to wherein Ris an aryl group having 6 to 20 carbon atoms claim 1 , a 5- to 8-membered monocyclic heteroaryl group or a polycyclic or condensed ring heteroaryl group claim 1 , each heteroaryl group having 2 to 15 carbon atoms and at least one heteroatom claim 1 , such as a nitrogen atom claim 1 , an oxygen atom claim 1 , and a sulfur atom claim 1 , or a phenyl group substituted with an alkyl group claim 1 , an alkenyl group claim 1 , an alkoxy group claim 1 , a halogen atom claim 1 , a nitro group claim 1 , or an aryl group.3. The production process according to wherein Ris hydrogen or a hydrocarbon group.4. The production process according to wherein MZis Cu(OTf).5. The production process according to wherein the reaction is performed in the presence of a base.6. The production process according to wherein the reaction is performed in the presence of an organic solvent. The present invention relates to a process for producing an optically active oxazoline or a salt thereof, which is useful as an intermediate for the synthesis of pharmaceuticals, agrochemicals, and various other chemicals, and also relates to an optically active oxazoline or a salt thereof produced by the process, and optical resolution of an oxazoline.Since optically active oxazolines are useful as a building block or a chiral ligand for organic synthesis, various production processes have been examined. Known examples of such processes for producing optically activity oxazolines include the processes described in Non Patent Literature 1 to 3.However, each of the above processes needs an optically active compound as a starting material. That is, there has been a problem of high starting material costs, leading to high product prices. In addition, since the above production processes need multiple steps, there have been problems of requirement for large-scale production ...

Подробнее
09-01-2014 дата публикации

COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT

Номер: US20140012011A1
Принадлежит: Eisai R&D Management Co., Ltd.

The present invention provides methods for preparing TLR-4 receptor agonist E6020: 130.-. (canceled)3334.-. (canceled) This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application ser. No. 60/695,324, filed Jun. 30, 2005, which is incorporated herein by reference.Generally, vaccines have proven to be successful methods for the prevention of infectious diseases. Generally, they are cost effective, and do not induce antibiotic resistance to the target pathogen or affect normal flora present in the host. In many cases, such as when inducing anti-viral immunity, vaccines can prevent a disease for which there are no viable curative or ameliorative treatments available.Vaccines function by triggering the immune system to mount a response to an agent, or antigen, typically an infectious organism or a portion thereof that is introduced into the body in a non-infectious or non-pathogenic form. Once the immune system has been “primed” or sensitized to the organism, later exposure of the immune system to this organism as an infectious pathogen results in a rapid and robust immune response that destroys the pathogen before it can multiply and infect enough cells in the host organism to cause disease symptoms.The agent, or antigen, used to prime the immune system can be the entire organism in a less infectious state, known as an attenuated organism, or in some cases, components of the organism such as carbohydrates, proteins or peptides representing various structural components of the organism.In many cases, it is necessary to enhance the immune response to the antigens present in a vaccine in order to stimulate the immune system to a sufficient extent to make a vaccine effective, i.e., to confer immunity. Many protein and most peptide and carbohydrate antigens, administered alone, do not elicit a sufficient antibody response to confer immunity. Such antigens need to be presented to the immune system in such a way that they will be recognized as foreign ...

Подробнее
16-01-2014 дата публикации

Aminopropenoates as Fungicides

Номер: US20140018377A1
Принадлежит: Bayer Intellectual Property GmbH

This application claims priority to European Patent Application No. 09173304.8, filed Oct. 16, 2009, and the benefit of U.S. Provisional Application No. 61/253,091, filed Oct. 20, 2009, the disclosure of each of which is incorporated by reference herein in its entirety. 2. A composition claim 1 , comprising at least one aminopropenoate of the formula (I) according to claim 1 , and one or more extenders claim 1 , surfactant claim 1 , or combinations thereof.3. (canceled)4. A method for controlling unwanted microorganisms claim 1 , comprising applying at least one aminopropenoate of the formula (I) according to to the microorganisms claim 1 , their habitat claim 1 , or combinations thereof.5. A process for preparing a composition claim 1 , comprising mixing at least one aminopropenoate of the formula (I) according to with one or more extenders claim 1 , surfactants claim 1 , or combinations thereof.6. A method for controlling unwanted microorganisms on a transgenic plant claim 1 , comprising applying at least one aminopropenoate of the formula (I) according to to the transgenic plant claim 1 , its seed claim 1 , its habitat claim 1 , or combinations thereof.7. The aminopropenoate of the formula (I) according to claim 1 , wherein R represents R.8. The aminopropenoate of the formula (I) according to claim 1 , wherein R represents R.9. The aminopropenoate of the formula (I) according to claim 7 , wherein n represents 0 claim 7 , 1 or 2.10. The aminopropenoate of the formula (I) according to claim 1 , wherein m represents 1 or 2.11. The aminopropenoate of the formula (I) according to claim 1 , wherein Yis S or O.12. The aminopropenoate of the formula (I) according to claim 1 , wherein Yrepresents O or NRwherein Rrepresents hydrogen claim 1 , C-C-alkyl claim 1 , C-C-cycloalkyl claim 1 , C-C-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different claim 1 , C-C-cycloalkyl-C-C-alkyl claim 1 , C-C-alkenyl-C-C-alkyl claim 1 , C-C-alkynyl-C-C-alkyl ...

Подробнее
16-01-2014 дата публикации

CYTOCHROME P450 INHIBITORS AND USES THEREOF

Номер: US20140018401A1
Принадлежит: Angion Biomedica Corp

The present invention provides compounds having the general structural formula (I) 185-. (canceled)87. The method of wherein X is imidazolyl claim 86 , triazolyl claim 86 , 3-pyridinyl or 4-pyridinyl.88. The method of wherein Gis hydrogen claim 86 , di(Calkyl)amino or saturated heterocycle.89. The method of wherein Rand Rare independently Calkyl.90. The method of wherein Qis —COOH or —COOR.92. The method of claim 91 , selected from the group consisting of: 3-(((6-(-2-(Dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoic acid; 3-((6-(-2-(Dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)-2 claim 91 ,2-dimethylpropanoic acid; 3-((6-(-2-(Dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)benzoic acid; 4-(((6-(-2-(Dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoic acid; 4-((6-(-2-(Dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)benzoic acid; Isopropyl 3-(((6-(-2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoate; Isopropyl 4-(((6-(-2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoate; Ethyl 3-(((6-(2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoate; Methyl 3-(((6-(-2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoate; Isopropyl 3-((6-(2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)-2 claim 91 ,2-dimethylpropanoate; Methyl 3-((6-(-2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)benzoate; Methyl 4-(((6-(-2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)methyl)benzoate; and Methyl 4-((6-(-2-(dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)amino)benzoate.94. The method of claim 93 , selected from the group consisting of: 1-((6-(-2-(Dimethylamino)-1-(1H-imidazol-1-yl)butyl)benzo[d]thiazol-2-yl)carbamoyl)cyclobutanecarboxylic acid; 1-((6-(-2-( ...

Подробнее
23-01-2014 дата публикации

1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase

Номер: US20140023663A1
Принадлежит: INCYTE CORPORATION

The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives. 1174-. (canceled)176. The method of claim 175 , wherein the antibody is an anti-CTLA-4 antibody.177. The method of claim 175 , wherein the antibody is an anti-PD-1 antibody.179. The method of claim 178 , wherein Ris NH.180. The method of claim 178 , wherein Ris Br.181. The method of claim 178 , wherein Ris F.182. The method of claim 178 , wherein n is 2.183. The method of claim 178 , wherein said compound is selected from:4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-1,2,5-oxadiazole-3-carboximidamide;4-({3-[(aminosulfonyl)amino]propyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-({3-[(methylsulfonyl)amino]propyl} amino)-1,2,5-oxadiazole-3-carboximidamide;4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}amino)-1,2,5-oxadiazole-3-carboximidamide;4-({3-[(aminosulfonyl)amino]propyl}amino)-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-(3-chloro-4-fluorophenyl)-N′-hydroxy-4-({3-[(methylsulfonyl)amino]propyl}amino)-1,2,5-oxadiazole-3-carboximidamide;4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide;N-[4-fluoro-3-(trifluoromethyl)phenyl]-N′-hydroxy-4-({2-[(methylsulfonyl)amino]ethyl}-amino)-1,2,5-oxadiazole-3-carboximidamide;4-({3-[(aminosulfonyl)amino]propyl}amino)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N′-hydroxy-1,2,5- ...

Подробнее
23-01-2014 дата публикации

Substituted Benzamides and Their Uses

Номер: US20140024649A1
Принадлежит:

Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use. 1111-. (canceled)113. The compound of selected from the group consisting of:4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(3-pyridinyl)benzamide;4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(4-pyridinyl)benzamide;N-Methyl-4-(5-methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(3-pyridinyl)benzamide;4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(2-pyridinylmethyl)benzamide;4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(4-pyridinylmethyl)benzamide;N-Methyl-4-(5-methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-[2-(3-pyridinyl)ethyl]benzamide;4-(5-Methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(2-pyrazinylmethyl)benzamide;N-[(1-Methyl-1H-imidazol-2-yl)methyl]-4-(5-methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)benzamide;N-[(1-Methyl-1H-imidazol-5-yl)methyl]-4-(5-methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)benzamide;4-{5-Methyl-4-[(phenylsulfonyl)methyl]-1,3-oxazol-2-yl}-N-(3-pyridinylmethyl)benzamide;4-(4-{[(4-Chlorophenyl)sulfonyl]methyl}-5-methyl-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(4-{[(4-tert-Butylphenyl)sulfonyl]methyl}-5-methyl-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(4-{[(3,5-Dimethylphenyl)sulfonyl]methyl}-5-methyl-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(4-{[(4-Bromophenyl)sulfonyl]methyl}-5-methyl-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(5-Methyl-4-{[(3-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(4-{[(4-Methoxyphenyl)sulfonyl]methyl}-5-methyl-1,3-oxazol-2-yl)-N-(3-pyridinylmethyl)benzamide;4-(5-Methyl-4-{[(3-methoxyphenyl)sulfonyl] ...

Подробнее